Document:

Form of Warrant - Loan and Security Agreement, dated July 30, 2008

 EXHIBIT 4.9 

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE
SECURITIES LAWS OF ANY STATE AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 5 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAW OR,
IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS EXEMPT FROM REGISTRATION. 

WARRANT TO PURCHASE STOCK 
  

			
	 Company: Complete Genomics, Inc., a Delaware corporation

Number of Shares: As set forth below

Class of Stock:  As set forth below

Warrant Price:  As set forth below

Issue Date:    July     , 2008

Expiration Date: July     , 2018

	 Credit Facility:
	 	 This Warrant is issued in connection with that certain Loan and Security Agreement of even date herewith among Silicon Valley Bank, Oxford Finance Corporation, Leader
Lending, LLC – Series A, Leader lending, LLC – Series B and the Company.

 THIS WARRANT
CERTIFIES THAT, for good and valuable consideration,
«LENDER» (together
 with any successor or permitted assignee or transferee of this Warrant or of any shares issued upon exercise hereof, is referred to hereinafter as “Holder”) is entitled to purchase the number of fully paid and non-assessable shares (the
“Shares”) of the above-stated Class of Stock (the “Class”) of the above-named company (the “Company”) at the above-stated Warrant Price, all as set forth above and as adjusted pursuant to Article 2 of this Warrant,
subject to the provisions and upon the terms and conditions set forth in this Warrant. 

A.      Number and Class of Shares; Warrant Price. 

(1)      Certain Definitions. As used herein, the following definitions have the respective
meanings set forth below: 
 “Acquisition” has the meaning given in Section 1.6.1 below. 

“IPO” means the Company’s initial, underwritten offering and sale of its shares to the public pursuant to an
effective registration statement under the Securities Act of 1933, as amended. 
 “Qualified Financing” means
the first sale or issuance by the Company after the Issue Date of this Warrant set forth above, in a single transaction or series of related transactions, of shares of its convertible preferred stock or other senior equity securities to one or more
investors for cash for financing purposes. 

 “Qualified Financing Securities” means the class and series of convertible
preferred stock or other senior equity security sold or issued by the Company in the Qualified Financing, and any securities of the Company into or for which the outstanding shares of such Qualified Financing Securities may be converted,
reclassified, reorganized or exchanged. 
 “Qualified Financing Price” means the lowest effective price per
share for which Qualified Financing Securities are sold or issued by the Company in the Qualified Financing. 

“Series C Price” means $5.31, subject to adjustment from time to time upon the occurrence of events described in Article
2 hereof. 
 “Series C Stock” shall mean the Company’s Series C Convertible Preferred Stock, $0.001 par
value per share, and any securities of the Company into or for which the outstanding shares of such Series C Convertible Preferred Stock may be converted, reclassified, reorganized or exchanged. 

(2)      Class of Shares. The class and series of the Company’s capital stock for which
this Warrant shall be exercisable (the “Class”) shall be Qualified Financing Securities; provided, that if, upon consummation of the Qualified Financing, the Qualified Financing Price shall be greater than the then-effective Series
C Price, then the “Class”: shall be Series C Stock from and after the consummation of such Qualified Financing; provided, further, that if, prior to the consummation of the Qualified Financing, there shall be an Acquisition
or IPO, then “Class” shall be Series C Stock as of immediately prior to (i) the effectiveness of the registration statement filed in connection with the IPO, or (ii) the closing of the Acquisition, as the case may be.
Notwithstanding the foregoing definition of Class, if Pay to Play Provisions are at any time applied to the outstanding shares of the Class, then from and after such application, “Class” shall mean that security that a holder of
outstanding shares of the Class prior to such application would have received had such holder participated in the manner necessary to receive or retain the security having the rights more favorable to the holder. As used herein, “Pay to Play
Provisions” means (a) provisions that require the holder of a security to participate in a subsequent round of equity financing or lose all or a portion of the benefit of antidilution protection applicable to a security or have such
security automatically convert to common stock or another series of capital stock, or (b) an exchange transaction having the same or similar economic effect. 

(3)      Warrant Price. The purchase price per Share hereunder (the “Warrant Price”)
shall be the Qualified Financing Price; provided, that if upon consummation of the Qualified Financing, the Qualified Financing Price shall be greater than the then-effective Series C Price, then the “Warrant Price” shall be the
Series C Price from and after the consummation of such Qualified Financing; provided, further, that if, prior to the consummation of the Qualified Financing, there shall be an Acquisition or IPO, then the “Warrant Price”
shall be the Series C Price as of immediately prior to (i) the effectiveness of the registration statement filed in connection with the IPO, or (ii) the closing of the Acquisition, as the case may be; and in any event subject to further
adjustment thereafter from time to time in accordance with the provisions of this Warrant. 

(4)      Number of Shares. The number of Shares for which this Warrant shall be exercisable
shall equal (i)             , divided by (ii) the Warrant Price as 

 

 2 

 
determined pursuant to paragraph A(3) above, and subject to further adjustment from time to time in accordance with the provisions of this Warrant. 

ARTICLE 1. EXERCISE. 

1.1      Method of Exercise. Holder may exercise this Warrant by delivering the original of
this Warrant together with a duly executed Notice of Exercise in substantially the form attached as Appendix 1 to the principal office of the Company. Unless Holder is exercising the conversion right set forth in Article 1.2, Holder shall also
deliver to the Company a check, wire transfer (to an account designated by the Company), or other form of payment acceptable to the Company for the aggregate Warrant Price for the Shares being purchased. 

1.2     Conversion Right. In lieu of exercising this Warrant as specified in Article 1.1, Holder
may from time to time convert this Warrant, in whole or in part, into a number of Shares determined by dividing (a) the aggregate fair market value of the Shares or other securities otherwise issuable upon exercise of this Warrant minus the
aggregate Warrant Price of such Shares by (b) the fair market value of one Share. The fair market value of the Shares shall be determined pursuant to Article 1.3. 

1.3     Fair Market Value. If the Company’s common stock is traded in a public market and the
Shares are common stock, the fair market value of a Share shall be the closing price of a share of common stock reported for the business day immediately before Holder delivers this Warrant together with its Notice of Exercise to the Company (or in
the instance where the Warrant is exercised immediately prior to the effectiveness of the Company’s IPO, the “price to public” per share price specified in the final prospectus relating to such offering). If the Company’s common
stock is traded in a public market and the Shares are preferred stock, the fair market value of a Share shall be the closing price of a share of the Company’s common stock reported for the business day immediately before Holder delivers this
Warrant together with its Notice of Exercise to the Company (or, in the instance where the Warrant is exercised immediately prior to the effectiveness of the IPO, the initial “price to public” per share price specified in the final
prospectus relating to such offering), in both cases, multiplied by the number of shares of the Company’s common stock into which a Share is convertible. If the Company’s common stock is not traded in a public market, the Board of
Directors of the Company shall determine fair market value in its reasonable good faith judgment. 

1.4     Delivery of Certificate and New Warrant. Promptly after Holder exercises or converts this
Warrant and, if applicable, the Company receives payment of the aggregate Warrant Price, the Company shall deliver to Holder certificates for the Shares acquired and, if this Warrant has not been fully exercised or converted and has not expired, a
new Warrant representing the Shares not so acquired. 
 1.5     Replacement of Warrants.
On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form and
amount to the Company or, in the case of mutilation, on surrender and cancellation of this Warrant, the Company shall execute and deliver, in lieu of this Warrant, a new warrant of like tenor. 

 

 3 

 1.6      Treatment of Warrant Upon Acquisition of
Company. 
 1.6.1     “Acquisition”. For the purpose of this Warrant,
“Acquisition” means any sale, license, or other disposition of all or substantially all of the assets of the Company, or any reorganization, consolidation, merger or sale of outstanding capital stock of the Company where the holders of the
Company’s securities before the transaction beneficially own less than a majority of the outstanding voting securities of the surviving entity after the transaction. 

1.6.2    Treatment of Warrant at Acquisition. 

A)      Upon the written request of the Company, Holder agrees that, in the event of an Acquisition in which the sole
consideration is cash, either (a) Holder shall exercise its conversion or purchase right under this Warrant and such exercise will be deemed effective immediately prior to the consummation of such Acquisition or (b) if Holder elects not to
exercise the Warrant, this Warrant will expire upon the consummation of such Acquisition. The Company shall provide the Holder with written notice of its request relating to the foregoing (together with such reasonable information as the Holder may
request in connection with such contemplated Acquisition giving rise to such notice), which is to be delivered to Holder not less than ten (10) days prior to the closing of the proposed Acquisition. 

B)      Upon the written request of the Company, Holder agrees that, in the event of an Acquisition that is an
“arms length” sale of all or substantially all of the Company’s assets (and only its assets) to a third party that is not an Affiliate (as defined below) of the Company (a “True Asset Sale”), either (a) Holder shall
exercise its conversion or purchase right under this Warrant and such exercise will be deemed effective immediately prior to the consummation of such Acquisition or (b) if Holder elects not to exercise the Warrant, this Warrant will continue
until the Expiration Date if the Company continues as a going concern following the closing of any such True Asset Sale. The Company shall provide the Holder with written notice of its request relating to the foregoing (together with such reasonable
information as the Holder may request in connection with such contemplated Acquisition giving rise to such notice), which is to be delivered to Holder not less than ten (10) days prior to the closing of the proposed Acquisition. 

C)      Holder agrees that, in the event of an Acquisition of the Company by an acquirer whose securities are
publicly traded if the acquirer in the Acquisition does not agree to assume this Warrant at and as of the closing thereof, and if, on the record date for the Acquisition, the fair market value of the Shares (or other securities issuable upon
exercise of this Warrant) based on the amount to be paid to holders of the Shares if the Warrant had been exercised, is equal to or greater than three (3) times the Warrant Price, Company may deem the Warrant to be automatically exercised and
the Holder shall participate in the Acquisition as a holder of the Shares (or other securities issuable upon exercise of the Warrant) on the same terms as other holders of the same class of securities of the Company. 

D)      Upon the closing of any Acquisition other than those particularly described in subsections (A), (B) and
(C) above, the successor entity shall assume the obligations of this Warrant, and this Warrant shall be exercisable for the same securities, cash, and 

 

 4 

 
property as would be payable for the Shares issuable upon exercise of the unexercised portion of this Warrant as if such Shares were outstanding on the record date for the Acquisition and
subsequent closing. The Warrant Price and/or number of Shares shall be adjusted accordingly. 
 As used in this Section 1.6,
“Affiliate” shall mean any person or entity that owns or controls directly or indirectly ten percent (10%) or more of the stock of Company, any person or entity that controls or is controlled by or is under common control with
such persons or entities, and each of such person’s or entity’s officers, directors, joint venturers or partners, as applicable. 

ARTICLE 2. ADJUSTMENTS TO THE SHARES. 

2.1      Stock Dividends, Splits, Etc.  If the Company declares or pays a dividend on
the outstanding shares of the Class payable in common stock or other securities, then upon exercise of this Warrant, for each Share acquired, Holder shall receive, without cost to Holder, the total number and kind of securities to which Holder would
have been entitled had Holder owned the Shares of record as of the date the dividend occurred. If the Company subdivides the outstanding shares of the Class by reclassification or otherwise into a greater number of shares or takes any other action
which increase the amount of common stock into which the one share of the Class is convertible, the number of Shares purchasable hereunder shall be proportionately increased and the Warrant Price shall be proportionately decreased. If the
outstanding shares of the Class are combined or consolidated, by reclassification or otherwise, into a lesser number of shares, the Warrant Price shall be proportionately increased and the number of Shares shall be proportionately decreased.

 2.2      Reclassification, Exchange, Combinations or Substitution.  Upon
any reclassification, exchange, substitution, or other event that results in a change of the number and/or class of the securities issuable upon exercise or conversion of this Warrant, Holder shall be entitled to receive, upon exercise or conversion
of this Warrant, the number and kind of securities and property that Holder would have received for the Shares if this Warrant had been exercised immediately before such reclassification, exchange, substitution, or other event. Such an event shall
include any automatic conversion of the outstanding or issuable securities of the Company of the same class or series as the Shares to common stock pursuant to the terms of the Company’s Certificate of Incorporation upon the closing of a
registered public offering of the Company’s common stock, but shall not include any conversions or reclassification as a result of a failure to participate in any equity financings of the Company or any “right of first refusal” or
other pay to play provisions set forth in the Company’s Third Restated Certificate of Incorporation, as it may be amended from time to time, including Section Fourth.B.3(c) thereof. The Company or its successor shall promptly issue to Holder an
amendment to this Warrant setting forth the number and kind of such new securities or other property issuable upon exercise or conversion of this Warrant as a result of such reclassification, exchange, substitution or other event that results in a
change of the number and/or class of securities issuable upon exercise or conversion of this Warrant. The amendment to this Warrant shall provide for adjustments which shall be as nearly equivalent as may be practicable to the adjustments provided
for in this Article 2 including, without limitation, adjustments to the Warrant Price and to the number of securities or property issuable upon exercise of the new Warrant. The provisions of this

  

 5 

 
Article 2.2 shall similarly apply to successive reclassifications, exchanges, substitutions, or other events. 

2.3      Adjustments for Diluting Issuances. The number of shares of common stock issuable
upon conversion of the Shares shall be subject to adjustment, from time to time in the manner set forth in the Company’s Certificate of Incorporation as if the Shares were issued and outstanding on and as of the date of any such required
adjustment. The provisions set forth for the Class in the Company’s Certificate of Incorporation relating to the above in effect as of the Issue Date may not be amended, modified or waived, without the prior written consent of Holder unless
such amendment, modification or waiver affects the rights associated with the Shares in the same manner as such amendment, modification or waiver affects the rights associated with all other shares of the Class. 

2.4      No Impairment. Except and to the extent waived or consented to in writing by Holder,
or as otherwise specifically permitted under the terms hereof, the Company shall not, by amendment of its Certificate of Incorporation or through a reorganization, transfer of assets, consolidation, merger, dissolution, issue, or sale of securities
or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed under this Warrant by the Company, but shall at all times in good faith assist in carrying out of all the provisions
of this Article 2 and in taking all such action as may be necessary or appropriate to protect Holder's rights under this Article against impairment. 

2.5      Fractional Shares. No fractional Shares shall be issuable upon exercise or conversion
of the Warrant and the number of Shares to be issued shall be rounded down to the nearest whole Share. If a fractional share interest arises upon any exercise or conversion of the Warrant, the Company shall eliminate such fractional share interest
by paying Holder the amount computed by multiplying the fractional interest by the fair market value of a full Share. 

2.6      Certificate as to Adjustments. Upon each adjustment of the Warrant Price, Class
and/or number of Shares, the Company shall promptly notify Holder in writing, and, at the Company’s expense, promptly compute such adjustment, and furnish Holder with a certificate of its Chief Financial Officer setting forth such adjustment
and the facts upon which such adjustment is based. The Company shall, upon written request, furnish Holder a certificate setting forth the Warrant Price, Class and number of Shares in effect upon the date thereof and the series of adjustments
leading to such Warrant Price, Class and number of Shares. 
 ARTICLE 3. REPRESENTATIONS AND COVENANTS OF THE COMPANY. 

3.1      Representations and Warranties. The Company represents and warrants to, and agrees
with, the Holder as follows: 
 (a)      The initial Warrant Price referenced on the first
page of this Warrant is not greater than the lowest effective price per share at which shares of the same class and series as the Shares were last issued in an arms-length transaction in which at least $500,000 of such shares were sold. 

 

 6 

 (b)       All Shares which may be issued upon the
exercise of the purchase right represented by this Warrant, and all securities, if any, issuable upon conversion of the Shares, shall, upon issuance, be duly authorized, validly issued, fully paid and non-assessable, and free of any liens and
encumbrances except for restrictions on transfer provided for herein or under applicable federal and state securities laws. 

(c)       The Company’s capitalization table attached hereto as Schedule 1 is true and
complete as of the Issue Date. 
 3.2       Notice of Certain Events.  If
the Company proposes at any time (a) to declare any dividend or distribution upon the outstanding shares of the Class, whether in cash, property, stock, or other securities and whether or not a regular cash dividend; (b) to offer for
subscription or sale pro rata to the holders of the outstanding shares of the Class any additional shares of any class or series of the Company’s stock; (c) to effect any reclassification, reorganization or recapitalization of the shares
of the Class; (d) to effect an Acquisition or to liquidate, dissolve or wind up; or (e) offer holders of registration rights the opportunity to participate in an underwritten public offering of the Company’s securities for cash, then,
in connection with each such event, the Company shall give Holder: (1) at least 10 days prior written notice of the date on which a record will be taken for such dividend, distribution, or subscription rights (and specifying the date on which
the holders of shares of the same class and series as the Shares will be entitled thereto) or for determining rights to vote, if any, in respect of the matters referred to in (c) and (d) above; (2) in the case of the matters referred
to in (c) and (d) above at least 10 days prior written notice of the date when the same will take place (and specifying the date on which the holders of shares of the same class and series as the Shares will be entitled to exchange their
shares for the securities or other property deliverable upon the occurrence of such event); and (3) in the case of the matter referred to in (e) above, the same notice as is given to the holders of such registration rights. 

3.3      Registration Under Securities Act of 1933, as amended.  The Company agrees
that the Shares or, if the Shares are convertible into common stock of the Company, such common stock, shall have certain incidental, or “Piggyback,” and S-3 registration rights pursuant to and as set forth in the Company’s Second
Amended and Restated Investor Rights Agreement, dated as of February 12, 2008 (the “Investor Rights Agreement”) as may be amended from time to time. Holder agrees to become a party to the Investor Rights Agreement for the purpose of
this Section 3.3 in an amendment acceptable to Holder. Company’s Investor Rights Agreement or similar agreement. The provisions set forth in the Investor Rights Agreement relating to the above in effect as of the Issue Date may not be
amended, modified or waived without the prior written consent of Holder unless such amendment, modification or waiver affects the rights associated with the Shares in the same manner as such amendment, modification, or waiver affects the rights
associated with all other shares of the same series and class as the Shares granted to the Holder. 

3.4      No Shareholder Rights.  Except as provided in this Warrant, Holder will not
have any rights as a shareholder of the Company until the exercise of this Warrant. 

3.5       Certain Information.  The Company agrees to provide Holder at any time and
from time to time with such information as Holder may reasonably request 
  

 7 

 
for purposes of Holder’s compliance with regulatory, accounting and reporting requirements applicable to Holder. 

ARTICLE 4. REPRESENTATIONS, WARRANTIES OF THE HOLDER.  The Holder represents and warrants to the Company as follows: 

4.1      Purchase for Own Account. This Warrant and the securities to be acquired upon exercise
of this Warrant by Holder will be acquired for investment for Holder’s account, not as a nominee or agent, and not with a view to the public resale or distribution within the meaning of the Act. Holder also represents that it has not been
formed for the specific purpose of acquiring this Warrant or the Shares. 

4.2      Disclosure of Information. Holder has received or has had full access to all the
information it considers necessary or appropriate to make an informed investment decision with respect to the acquisition of this Warrant and its underlying securities. Holder further has had an opportunity to ask questions and receive answers from
the Company regarding the terms and conditions of the offering of this Warrant and its underlying securities and to obtain additional information (to the extent the Company possessed such information or could acquire it without unreasonable effort
or expense) necessary to verify any information furnished to Holder or to which Holder has access. 

4.3      Investment Experience. Holder understands that the purchase of this Warrant and its
underlying securities involves substantial risk. Holder has experience as an investor in securities of companies in the development stage and acknowledges that Holder can bear the economic risk of such Holder’s investment in this Warrant and
its underlying securities and has such knowledge and experience in financial or business matters that Holder is capable of evaluating the merits and risks of its investment in this Warrant and its underlying securities and/or has a preexisting
personal or business relationship with the Company and certain of its officers, directors or controlling persons of a nature and duration that enables Holder to be aware of the character, business acumen and financial circumstances of such persons.

 4.4      Accredited Investor Status. Holder is an “accredited investor”
within the meaning of Regulation D promulgated under the Act. 
 4.5      The Act.
Holder understands that this Warrant and the Shares issuable upon exercise or conversion hereof have not been registered under the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide
nature of the Holder’s investment intent as expressed herein. Holder understands that this Warrant and the Shares issued upon any exercise or conversion hereof must be held indefinitely unless subsequently registered under the Act and qualified
under applicable state securities laws, or unless exemption from such registration and qualification are otherwise available. 

4.6      Market Stand-Off Agreement. Holder hereby agrees to be bound by the terms and
conditions of the market standoff agreement, currently section 1.14, of the Investor Rights Agreement, as it may be amended from time to time. The provisions set forth in the Company’s Investors’ Right Agreement relating to the above in
effect as of the Issue Date may not be amended, modified or waived without the prior written consent of Holder if such amendment, modification or waiver affects the rights associated with the Shares in a manner adversely different than such
amendment, 
  

 8 

 
modification, or waiver affects the rights associated with the other shares of the same series and class as the Shares granted to Holder. 

ARTICLE 5. MISCELLANEOUS. 

5.1      Term:  This Warrant is exercisable in whole or in part at any time and from
time to time on or before the Expiration Date. 
 5.2      Legends.  This
Warrant and the Shares (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) shall be imprinted with a legend in substantially the following form: 

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE ACT, OR THE SECURITIES LAWS OF ANY STATE AND,
EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 5 OF THAT CERTAIN WARRANT TO PURCHASE STOCK ISSUED BY THE COMPANY TO SILICON VALLEY BANK DATED AS OF
                    , MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT
AND APPLICABLE STATE SECURITIES LAW OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS EXEMPT FROM REGISTRATION. 

5.3      Compliance with Securities Laws on Transfer.  This Warrant and the Shares
issuable upon exercise of this Warrant (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole or in part without compliance with applicable federal and state
securities laws by the transferor and the transferee (including, without limitation, the delivery of investment representation letters and legal opinions reasonably satisfactory to the Company, as reasonably requested by the Company). The Company
shall not require Holder to provide an opinion of counsel if the transfer is to SVB Financial Group (Silicon Valley Bank’s parent company) or any other affiliate of Holder, provided that any such transferee is an “accredited investor”
as defined in Regulation D promulgated under the Act. 
 5.4 Transfer Procedure.  After receipt by
Silicon Valley Bank (“Bank”) of the executed Warrant, Bank will transfer all of this Warrant to SVB Financial Group, Holder's parent company. Subject to the provisions of Article 5.3 and upon providing the Company with written notice, SVB
Financial Group and any subsequent Holder may transfer all or part of this Warrant or the Shares issuable upon exercise of this Warrant (or the securities issuable directly or indirectly, upon conversion of the Shares, if any) to any transferee,
provided, however, in connection with any such transfer, SVB Financial Group or any subsequent Holder will give the Company notice of the portion of the Warrant being transferred with the name, address and taxpayer identification number of the
transferee and Holder will surrender this Warrant to the Company for reissuance to the transferee(s) (and Holder if applicable). The Company may refuse to transfer this 

 

 9 

 
Warrant or the Shares to any person who directly competes with the Company, unless, in either case, the stock of the Company is publicly traded. 

5.5      Notices.  All notices and other communications from the Company to the
Holder, or vice versa, shall be deemed delivered and effective when given personally or mailed by first-class registered or certified mail, postage prepaid (or on the first business day after transmission by facsimile), at such address as may have
been furnished to the Company or Holder, as the case may be, in writing by the Company or such holder from time to time. All notices to Holder shall be addressed as follows until the Company receives notice of a change of address in connection with
a transfer or otherwise: 

«LENDER»
 

Notice to the Company shall be addressed as follows until Holder receives notice of a change in address: 

Complete Genomics, Inc. 

Attn: Chief Financial Officer 

2071 Stierlin Court 

Mountain View, CA 94043 

Telephone: 650-943-2843 

Facsimile: 650-964-2108 

5.6      Waiver.  This Warrant and any term hereof may be changed, waived,
discharged or terminated only by an instrument in writing signed by the party against which enforcement of such change, waiver, discharge or termination is sought. 

5.7      Attorney’s Fees.  In the event of any dispute between the parties
concerning the terms and provisions of this Warrant, the party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys’ fees. 

5.8      Automatic Conversion upon Expiration.  In the event that, upon the
Expiration Date, the fair market value of one Share (or other security issuable upon the exercise hereof) as determined in accordance with Section 1.3 above is greater than the Warrant Price in effect on such date, then this Warrant shall
automatically be deemed on and as of such date to be converted pursuant to Section 1.2 above as to all Shares (or such other securities) for which it shall not previously have been exercised or converted, and the Company shall promptly deliver
a certificate representing the Shares (or such other securities) issued upon such conversion to Holder. 

5.9      Counterparts.  This Warrant may be executed in counterparts, all of which
together shall constitute one and the same agreement. 
 [Remainder of page left blank intentionally] 

 

 10 

 5.10    Governing Law.  This Warrant shall be
governed by and construed in accordance with the laws of the State of California, without giving effect to its principles regarding conflicts of law. 
  

			
	 “COMPANY”

	
	 COMPLETE GENOMICS, INC.

		
	 By:
	 	  

		
	 Name:
	 	  

		 	 (Print)

	 Title:
	 	
	
	 “HOLDER”

	
	
«LENDER»

		
	 By:
	 	  

		
	 Name:
	 	  

		 	 (Print)

	 Title:
	 	

  

 11 

 APPENDIX 1 

NOTICE OF EXERCISE 

1.      Holder elects to purchase
                     shares of the Common/Series              Preferred
[strike one] Stock of
                                        
pursuant to the terms of the attached Warrant, and tenders payment of the purchase price of the shares in full. 
 [or]

 1.      Holder elects to convert the attached Warrant into Shares/cash [strike one] in the
manner specified in the Warrant. This conversion is exercised for
                                     of the Shares covered by
the Warrant. 
 [Strike paragraph that does not apply.] 

2.      Please issue a certificate or certificates representing the Shares in the name specified
below: 
  

					
		 	  
	 	
		 	 Holder’s Name
	 	
			
		 	  
	 	
			
		 	  
	 	
		 	 (Address)
	 	

 3.      By its execution below and for the benefit of the
Company, Holder hereby restates each of the representations and warranties in Article 4 of the Warrant as of the date hereof. 
  

			
	 HOLDER:

	  

		
	 By:
	 	  

		
	 Name:
	 	  

		
	 Title:
	 	  

		
	 (Date):
	 	  

 

 12 

 SCHEDULE
1 
 Company Capitalization Table
 
 See
attached 
  

 13Third Amended and Restated Investor Rights Agreement

 EXHIBIT 10.1 

THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

This Third Amended and Restated Investor Rights Agreement (this “Agreement”) is made as of August 12,
2009, among Complete Genomics, Inc., a Delaware corporation (the “Company”), the stockholders and warrantholders listed on Exhibit A hereto (each, an “Investor” and collectively, the
“Investors”) and the stockholders and founders of the Company listed on Exhibit B hereto (each, a “Founder” and collectively, the “Founders”). 

RECITALS 

The Company and certain of the Investors have entered into a Series D Preferred Stock Purchase Agreement (the “Purchase
Agreement”) of even date herewith pursuant to which the Company wants to sell to such Investors and such Investors want to purchase from the Company shares of the Company’s Series D Preferred Stock. One condition to such
Investors’ obligations to purchase shares of the Company’s Series D Preferred Stock under the Purchase Agreement is that the Company and such Investors enter into this Agreement in order to provide such Investors with certain rights to
register shares of the Company’s Common Stock issuable upon conversion of the Series D Preferred Stock held by such Investors, certain rights to receive information pertaining to the Company, and a right of first offer with respect to certain
issuances by the Company of its securities. The Company wants to induce such Investors to purchase shares of Series D Preferred Stock pursuant to the Purchase Agreement by agreeing to the terms and conditions set forth herein. 

The Company, the Investors and the Founders previously entered into that certain Second Amended and Restated Investor Rights Agreement
dated February 12, 2008, as amended February 13, 2009 (the “Prior Agreement”). The parties to the Prior Agreement desire to amend and restate the Prior Agreement in its entirety, and to accept the rights and
restrictions created in this Agreement in lieu of the rights and restrictions contained in the Prior Agreement. Section 4.10 of the Prior Agreement vested the authority to amend the Prior Agreement in the Company and the Holder or Holders (as
defined in the Prior Agreement) holding, in the aggregate, more than a majority of the outstanding shares of the Registrable Securities (as defined in the Prior Agreement) held by the Holders. The Holders holding more than a majority of the
Registrable Securities are entering into this Agreement, making this Agreement binding upon all of the parties to the Prior Agreement. 

AGREEMENT 

The parties agree as follows: 

1. Restrictions on Transferability; Registration Rights. 

1.1 Certain Definitions. As used in this Agreement, the following terms have the following respective meanings: 

“Board” means the board of directors of the Company. 

“Commission” means the Securities and Exchange Commission or any other federal agency at the time administering
the Securities Act. 

 “Exchange Act” means the Securities Exchange Act of 1934, as
amended, or any similar successor federal statute, and the rules and regulations thereunder, all as the same shall be in effect from time to time. 

“Form S-3 Initiating Holders” means any Holder or Holders who in the aggregate hold not less than five percent
(5%) of the Registrable Securities then outstanding and who propose to register securities, the aggregate offering price of which exceeds $5,000,000. 

“Gold Hill” shall mean Gold Hill Venture Lending 03, L.P. 

“Gold Hill Warrant” shall mean the warrant issued to Gold Hill in connection with the Loan and Security Agreement
by and among the Company, SVB and Gold Hill, dated as of September 21, 2006. 
 “Holder” means
(i) any Investor or Founder holding Registrable Securities; (ii) SVB and Gold Hill; provided, however, that SVB and Gold Hill shall not be deemed Holders for purposes of Sections 1.3, 2 and 3 of this Agreement except with respect to the
Shares of Series C Preferred Stock held by Gold Hill and the Common Stock issuable upon conversion thereof; and (iii) any person holding Registrable Securities to whom the rights under this Agreement have been transferred in accordance with
Section 1.11 hereof. 
 “Initiating Holders” means any Holder or Holders who in the aggregate hold
not less than forty percent (40%) of the Registrable Securities then outstanding and who propose to register securities, the aggregate offering price of which, net of underwriting discounts and commissions, exceeds $5,000,000. 

“IPO” means the first public offering of the Common Stock of the Company to the general public that is affected
pursuant to a registration statement filed with, and declared effective by, the Commission under the Securities Act. 

“Major Investors” means Essex Woodlands Health Ventures Fund VIII, L.P., Essex Woodlands Health Ventures Fund
VIII-A, L.P. and Essex Woodlands Health Ventures Fund VIII-B, L.P. (any of them, “Essex”), OrbiMed Associates III, LP and Caduceus Private Investments III, LP (either, “OrbiMed”), Highland Capital
Management, L.P. (“Highland”), Prospect Venture Partners III, L.P., OVP Venture Partners VI, L.P. and Enterprise Partners VI, LP and Genentech, Inc., together with their respective affiliates; provided, however, that
Genentech, Inc. shall not be a Major Investor for the purposes of Sections 2 or 3 hereof. 
 “New
Securities” means any shares of capital stock of the Company, including Common Stock and Preferred Stock, whether authorized or not, and rights, options, or warrants to purchase said shares of capital stock, and securities of any type
whatsoever that are, or may become, convertible into capital stock; provided, however, that the term “New Securities” does not include (i) the issuance of Common Stock upon the conversion of any bonds, debentures, notes
or other evidence of indebtedness, and any warrants shares or any other securities convertible into, exercisable for, or exchangeable for Common Stock, including Preferred Stock (collectively, “Convertible Securities”),
outstanding as of the date hereof; (ii) the issuance of shares as approved by the Board (including at least three of the Preferred Directors) of Common Stock (or options to purchase shares of Common Stock) to employees, officers, directors or

  

 2 

 
consultants of the Company under equity incentive plans, programs or agreements approved by the Board (not including the reissuance of shares repurchased by the Company from employees or
consultants of the Company); (iii) the issuance of shares of Common Stock or Convertible Securities to lenders, financial institutions, equipment lessors, or real estate lessors to the Company in connection with commercial credit arrangements,
equipment financings, commercial property leases or similar transactions approved by the Board; (iv) the issuance of shares of Common Stock or Convertible Securities pursuant to (A) the acquisition of another business by the Company by
merger, purchase of substantially all of the assets or shares, or other reorganization whereby the Company or its shareholders own not less than a majority of the voting power of the surviving or successor business or (B) the acquisition of
technology or other intellectual property by outright purchase or exclusive license, in each case, provided that such transaction is approved by the Board; (v) the issuance of shares of Common Stock in connection with a Qualified IPO;
(vi) the issuance of shares of Common Stock or Convertible Securities in connection with strategic partnership transactions approved by the Board; (vii) the issuance of shares pursuant to stock splits, stock dividends or similar
transactions; or (viii) securities issued pursuant to the Purchase Agreement. 
 “Other
Stockholders” means persons other than Holders who, by virtue of agreements with the Company, are entitled to include their securities in certain registrations hereunder. 

“Preferred Director” has the meaning set forth in the Restated Certificate. 

“Pro Rata Portion” means the ratio that (x) the sum of the number of shares of the Company’s Common
Stock held by an Investor immediately prior to the issuance of New Securities, assuming conversion of the Shares but excluding any other security of the Company exercisable for, or convertible into, Common Stock, bears to (y) the sum of the
total number of shares of the Company’s Common Stock then outstanding, assuming conversion of the Shares but excluding any other security of the Company exercisable for, or convertible into, Common Stock then outstanding. 

The terms “register”, “registered” and “registration” refer to a
registration effected by preparing and filing a registration statement in compliance with the Securities Act, and the declaration or ordering of the effectiveness of such registration statement. 

“Qualified IPO” shall have the meaning set forth in the Restated Certificate. 

“Registration Expenses” shall mean all expenses incurred by the Company in complying with Sections 1.3, 1.4, and
1.5 hereof, including, without limitation, all registration, qualification, listing and filing fees, printing expenses, escrow fees, fees and disbursements of counsel for the Company, fees and disbursements of one counsel for all of the
Holders registering securities in any given registration, blue sky fees and expenses, and the expense of any special audits incident to or required by any such registration (but excluding the compensation of regular employees of the Company which
shall be paid in any event by the Company), but shall not include Selling Expenses. 
  

 3 

 “Registrable Securities” shall mean (i) shares of Common Stock
issued or issuable pursuant to the conversion of the Shares, (ii) shares of Series B Preferred Stock issued upon exercise of the SVB Warrant or the Gold Hill Warrant; provided, however, that such shares shall not be deemed Registrable
Securities and the holders thereof shall not be deemed Holders for purposes of Sections 1.3, 2 and 3 of this Agreement; (iii) any Common Stock of the Company issued as a dividend or other distribution with respect to or in exchange for or in
replacement of the shares referenced in clauses (i) and (ii) above; and (iv) solely for the purposes of Section 1.5, shares of Common Stock issued or issuable to the Founders and to Callida Genomics, Inc.; provided,
however, that shares of Common Stock or other securities shall only be treated as Registrable Securities if and so long as they have not been (A) sold to or through a broker or dealer or underwriter in a public distribution or a public
securities transaction, (B) transferred in a transaction pursuant to which the registration rights are not also assigned in accordance with Section 1.11 hereof, or (C) with respect to each Holder, all such shares held by such Holder
become eligible for sale immediately under Rule 144 of the Securities Act (or any successor rule). 
 “Restricted
Securities” shall mean the securities of the Company required to bear the legend set forth in Section 1.2 hereof. 

“Rule 144” means Rule 144 as promulgated by the Commission under the Securities Act, as such Rule may be amended
from time to time, or any similar successor rule that may be promulgated by the Commission. 
 “Rule
145” means Rule 145 as promulgated by the Commission under the Securities Act, as such Rule may be amended from time to time, or any similar successor rule that may be promulgated by the Commission. 

“Securities Act” shall mean the Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder or any similar federal statute and the rules and regulations of the Commission thereunder, all as the same shall be in effect at the time. 

“Selling Expenses” shall mean all underwriting discounts, selling commissions and stock transfer taxes applicable
to the securities registered by the Holders and all fees and disbursements of counsel for any Holder, other than the fees and disbursements of one counsel for all of the Holders registering securities in any given registration as provided in the
definition of “Registration Expenses” above. 
 “Shares” means the Company’s Series A
Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock. 

“SVB” shall mean Silicon Valley Bank, and when SVB transfers the SVB Warrant to SVB Financial Group, shall be the
SVB Financial Group. 
 “SVB Warrant” shall mean the warrant issued to SVB in connection with the Loan
and Security Agreement by and among the Company, SVB and Gold Hill, dated as of September 21, 2006. 
  

 4 

 1.2 Restrictions. 

(a) Each Holder agrees not to make any disposition of all or any portion of the Registrable Securities unless and until the transferee
has agreed in writing for the benefit of the Company to be bound by this Section 1.2 and by Section 1.14 hereof, provided and to the extent such Sections are then applicable, and (i) there is then in effect a registration statement
under the Securities Act covering such proposed disposition and such disposition is made in accordance with such registration statement, or (ii) such Holder shall have notified the Company of the proposed disposition and shall have furnished
the Company with a detailed statement of the circumstances surrounding the proposed disposition, and, if reasonably requested by the Company, such Holder shall have furnished the Company with an opinion of counsel or other evidence reasonably
satisfactory to the Company, that such disposition will not require registration under the Securities Act. Notwithstanding the foregoing, no such registration statement or opinion of counsel shall be necessary for a transfer by a Holder which is
(A) a partnership to its partners or retired partners in accordance with partnership interests, (B) a limited liability company to its members or former members in accordance with their interest in the limited liability company, (C) a
corporation to its shareholders in accordance with their interests in the corporation, (D) to the Holder’s family member or trust for the benefit of an individual Holder, or (E) to any of its affiliates (including but not limited to
an affiliated fund managed by the same manager or managing member or general partner or management company or by an entity controlling, controlled by, or under common control with such manager or managing member or general partner or management
company, each an “Affiliated Entity”), provided in all cases enumerated in clauses (A) – (E) that the transferee is subject to the terms of this Section 1.2 and Section 1.14 as if such transferee were
an original Holder hereunder. Each Holder consents to the Company making a notation on its records and giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer established in this
Section 1.2. 
 (b) Each certificate representing Registrable Securities shall be stamped or otherwise imprinted with
legends substantially in the following forms (in addition to any legend required under applicable state securities laws or the Company’s charter documents): 

“THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT
OF 1933, AS AMENDED, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED, OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SUCH ACT, OR UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY
AND ITS COUNSEL, THAT SUCH REGISTRATION IS NOT REQUIRED.” 
 “THE SHARES REPRESENTED BY THIS CERTIFICATE MAY BE
TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE SHAREHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY.” 
  

 5 

 (c) The Company shall promptly reissue unlegended certificates at the request of any Holder
thereof if the Holder shall have obtained an opinion of counsel or other evidence reasonably acceptable to the Company to the effect that the securities proposed to be disposed of may lawfully be disposed of without registration, qualification, or
legend. 
 1.3 Requested Registration. 

(a) Request for Registration. If the Company shall receive from Initiating Holders a written request that the Company effect any
registration, qualification, or compliance, the Company will: 
 (i) promptly deliver written notice of the proposed
registration, qualification, or compliance to all other Holders; and 
 (ii) as soon as practicable, use its best efforts to
effect such registration, qualification, or compliance (including, without limitation, the execution of an undertaking to file post-effective amendments, appropriate qualification under applicable blue sky or other state securities laws, and
appropriate compliance with applicable regulations issued under the Securities Act and any other governmental requirements or regulations) as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of
such Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of any Holder or Holders joining in such request as are specified in a written request delivered to the Company within
twenty (20) days after delivery of such written notice from the Company; provided, however, that the Company shall not be obligated to take any action to effect any such registration, qualification, or compliance pursuant to this
Section 1.3: 
 (A) Prior to the earlier of: (i) three (3) years following the date of this Agreement, and
(ii) six months following the effective date of an IPO; 
 (B) After the Company has effected two (2) such
registrations pursuant to this Section 1.3, such registrations have been declared or ordered effective, and the securities offered pursuant to such registrations have been sold; 

(C) During the period starting with the date sixty (60) days prior to the Company’s estimated date of filing of, and ending on
a date one hundred and eighty (180) days after the effective date of, a registration initiated by the Company; provided that the Company (i) delivers notice of the Company’s intent to effect such registration to the Holders within
thirty (30) days after the Company’s receipt of the request of the Initiating Holders and is actively employing in good faith all reasonable efforts to cause such registration statement to become effective and that the Company’s
estimate of the date of filing such registration statement is made in good faith, and (ii) may not defer its registration obligations under Section 1.3 for more than an aggregate of Two Hundred Forty (240) days in any twelve
(12) month period pursuant to this Section 1.3(a)(ii)(C) and/or Section 1.3(a)(ii)(E); 
 (D) In any particular
jurisdiction in which the Company would be required to execute a general consent to service of process in effecting such 

 

 6 

 
registration, qualification or compliance unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(E) If in the good faith judgment of the Board, such registration would be seriously detrimental to the Company and the Board concludes,
as a result, that it is essential to defer the filing of such registration statement at such time, and the Company thereafter delivers to the Initiating Holders a certificate, signed by the President or Chief Executive Officer of the Company,
stating that in the good faith judgment of the Board it would be seriously detrimental to the Company or its stockholders for a registration statement to be filed in the near future, then the Company’s obligation to use its best efforts to
register, qualify, or comply under this Section 1.3 shall be deferred for a period, not to exceed sixty (60) days from the delivery of the written request from the Initiating Holders, during which such filing would be seriously
detrimental; provided, however, that the Company (i) may not utilize this right more than twice in any twelve (12) month period, and (ii) may not defer its registration obligations under Section 1.3 for more than an
aggregate of Two Hundred Forty (240) days in any twelve (12) month period pursuant to this Section 1.3(a)(ii)(E) and/or Section 1.3(a)(ii)(C); 

(F) If the Initiating Holders do not request that such offering be firmly underwritten by underwriters selected by the Initiating
Holders (subject to the consent of the Company, which consent will not be unreasonably withheld or delayed); or 
 (G) If the
Initiating Holders propose to dispose of shares of Registrable Securities which may be immediately registered on Form S-3 pursuant to a request made under Section 1.4 hereof. 

Subject to the foregoing clauses (A) through (G), the Company shall file a registration statement covering the Registrable
Securities so requested to be registered as soon as practicable after receipt of the request or requests of the Initiating Holders. The registration statement filed pursuant to the request of the Initiating Holders may, subject to the provisions of
Sections 1.3(c) hereof, include other securities of the Company with respect to which registration rights have been granted, and may include securities being sold for the account of the Company. For the avoidance of doubt, the Company may utilize
its right to defer registration under Section 1.3(a)(ii)(E) in two consecutive sixty (60) day periods in any twelve (12) month period to defer a requested registration for up to one hundred twenty (120) days (subject to the
limitation in Section 1.3(a)(ii)(E)(ii)). 
 (b) Underwriting. If the Initiating Holders request that such offering
be firmly underwritten by underwriters selected by the Initiating Holders (subject to the consent of the Company, which consent will not be unreasonably withheld), the right of any Holder to registration pursuant to this Section 1.3 shall be
conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. A Holder may elect to include in such underwriting all or a part
of the Registrable Securities held by such Holder. 
 (c) Procedures. The Initiating Holders shall, on behalf of all
Holders, offer to include such securities in the underwriting and may condition such offer on their acceptance of the applicable provisions of this Section 1 (including without limitation

  

 7 

 
Section 1.14). The Company shall (together with all Holders or other persons proposing to distribute their securities through such underwriting) enter into and perform its obligations under
an underwriting agreement in customary form with the managing underwriter selected for such underwriting by the Initiating Holders holding a majority of the then outstanding shares held by all Initiating Holders (which managing underwriter shall be
reasonably acceptable to the Company). Notwithstanding any other provision of this Agreement, if the managing underwriter advises the Initiating Holders in writing that marketing factors require a limitation of the number of shares to be
underwritten, the number of shares to be included in the underwriting or registration shall be allocated among all participating Holders thereof, including the Initiating Holders, in proportion (as nearly as practicable) to the amount of Registrable
Securities of the Company owned by each participating Holder. In no event shall any Registrable Securities be excluded from such underwriting unless all other securities are first excluded from such offering. If any person who has requested
inclusion in such registration as provided above disapproves of the terms of the underwriting, such person shall be excluded therefrom by written notice delivered by the Company or the managing underwriter. Any Registrable Securities and/or other
securities so excluded or withdrawn shall also be withdrawn from registration. 
 1.4 Registration on Form S-3.

 (a) Qualification on Form S-3. After the IPO, the Company shall use its best efforts to qualify for registration on
Form S-3 or any comparable or successor form. To that end the Company shall register (whether or not required by law to do so) its Common Stock under the Exchange Act in accordance with the provisions of the Exchange Act following the effective date
of the first registration of any securities of the Company on Form S-1 or any comparable or successor form or forms. 
 (b)
Request for Registration on Form S-3. After the Company has qualified for the use of Form S-3, if the Company shall receive from Form S-3 Initiating Holders a written request that the Company effect a registration on Form S-3 the Company
will: 
 (i) promptly deliver written notice of the proposed registration to all other Holders; and 

(ii) as soon as practicable, use its best efforts to effect such registration, qualification, or compliance (including, without
limitation, the execution of an undertaking to file post-effective amendments, appropriate qualification under applicable blue sky or other state securities laws, and appropriate compliance with applicable regulations issued under the Securities Act
and any other governmental requirements or regulations) as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such Registrable Securities as are specified in such request, together with all or
such portion of the Registrable Securities of any Holder or Holders joining in such request as are specified in a written request delivered to the Company within twenty (20) days after delivery of such written notice from the Company;
provided, however, that the Company shall not be obligated to take any action to effect any such registration, qualification, or compliance pursuant to this Section 1.4: 

(A) After the fifth anniversary of an IPO; 
  

 8 

 (B) After the Company has effected two (2) such registrations pursuant to this
Section 1.4 during any twelve (12) month period, such registrations have been declared or ordered effective and the securities offered pursuant to such registrations have been sold; 

(C) During the period starting with the date sixty (60) days prior to the Company’s estimated date of filing of, and ending on
a date one hundred and eighty (180) days after the effective date of, a registration initiated by the Company; provided that the Company (i) delivers notice of the Company’s intent to effect such registration to the Holders
within thirty (30) days after the Company’s receipt of the request of the Form S-3 Initiating Holders and is actively employing in good faith all reasonable efforts to cause such registration statement to become effective and that the
Company’s estimate of the date of filing such registration statement is made in good faith, and (ii) may not defer its registration obligations under Section 1.4 for more than an aggregate of Two Hundred Forty (240) days in any
twelve (12) month period pursuant to this Section 1.4(b)(ii)(C) and/or Section 1.4(b)(ii)(E); 
 (D) In any
particular jurisdiction in which the Company would be required to execute a general consent to service of process in effecting such registration, qualification, or compliance unless the Company is already subject to service in such jurisdiction and
except as may be required by the Securities Act; 
 (E) If in the good faith judgment of the Board, such registration would be
seriously detrimental to the Company and the Board concludes, as a result, that it is essential to defer the filing of such registration statement at such time, and the Company thereafter delivers to the Form S-3 Initiating Holders a certificate,
signed by the President or Chief Executive Officer of the Company, stating that in the good faith judgment of the Board it would be seriously detrimental to the Company or its stockholders for a registration statement to be filed in the near future,
then the Company’s obligation to use its best efforts to register, qualify, or comply under this Section 1.4 shall be deferred, for a period not to exceed sixty (60) days from the date of delivery of the written request from the Form
S-3 Initiating Holders, during which such filing would be seriously detrimental; provided, however, that the Company (i) may not utilize this right more than twice in any twelve (12) month period, and (ii) may not defer
its registration obligations under Section 1.4 for more than an aggregate of Two Hundred Forty (240) days in any twelve (12) month period pursuant to this Section 1.4(b)(ii)(E) and/or Section 1.4(b)(ii)(C). For the avoidance
of doubt, the Company may utilize its right to defer registration under Section 1.4(a)(ii)(E) in two consecutive sixty (60) day periods in any twelve (12) month period to defer a requested registration for up to one hundred twenty
(120) days (subject to the limitation in Section 1.4(a)(ii)(E)(ii)). 
 (c) Underwriting; Procedure. If a
registration requested under this Section 1.4 is for an underwritten offering, the provisions of Sections 1.3(b) and 1.3(c) shall apply to such registration. Registrations effected pursuant to this Section 1.4 shall not be counted as
demands for registration(s) effected pursuant to Sections 1.3 or 1.5, respectively. 
  

 9 

 1.5 Company Registration. 

(a) Notice of Registration. If the Company shall determine to register any of its securities, either for its own account or the
account of a security holder or holders other than (A) a registration pursuant to Sections 1.3 or 1.4 hereof, (B) a registration relating solely to employee benefit plans, (C) a registration relating solely to a Rule 145 transaction,
or (D) a registration on any registration form that does not permit secondary sales, the Company will: 
 (i) promptly
deliver to each Holder written notice thereof; and 
 (ii) use its best efforts to include in such registration (and any
related qualification under blue sky laws or other compliance), except as set forth in Section 1.5(b) below, and in any underwriting involved therein, all the Registrable Securities specified in a written request or requests made by any Holder
and delivered to the Company within twenty (20) days after the written notice is delivered by the Company. Such written request may include all or a portion of a Holder’s Registrable Securities. 

(b) Underwriting; Procedures. If the registration of which the Company gives notice is for a registered public offering involving
an underwriting, the Company shall so advise the Holders as a part of the written notice given pursuant to Section 1.5(a)(i). In such event, the right of any Holder to registration pursuant to this Section 1.5 shall be conditioned upon
such Holder’s participation in such underwriting and the inclusion of Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with
the Company and the other holders distributing their securities through such underwriting) enter into and perform their obligations under an underwriting agreement in customary form with the managing underwriter selected for such underwriting by the
Company. Notwithstanding any other provision of this Section 1.5, if the managing underwriter determines that marketing factors require a limitation of the number of shares to be underwritten, the managing underwriter may (subject to the
limitations set forth below) exclude Registrable Securities from, or limit the number of Registrable Securities to be included in, the registration and underwriting. The Company shall so advise all holders of securities requesting registration, and
the number of shares of securities that are entitled to be included in the registration and underwriting shall be allocated as set forth in Section 1.13. If any person who has requested inclusion in such registration as provided above
disapproves of the terms of the underwriting, such person shall be excluded therefrom by written notice delivered by the Company or the managing underwriter. Any Registrable Securities and/or other securities so excluded or withdrawn shall also be
withdrawn from registration. 
 (c) Right to Terminate Registration. The Company shall have the right to terminate or
withdraw any registration initiated by it under this Section 1.5 prior to the effectiveness of such registration, whether or not any Holder has elected to include securities in such registration. 

 

 10 

 1.6 Registration Procedures. In the case of each registration, qualification, or
compliance effected by the Company pursuant to this Section 1, the Company will keep each Holder advised in writing as to the initiation of each registration, qualification, and compliance and as to the completion thereof and, at its expense,
the Company will use its best efforts to: 
 (a) Prepare and file with the Commission a registration statement with respect to
such securities and use its best efforts to cause such registration statement to become and remain effective for at least one hundred eighty (180) days or until the distribution described in the registration statement has been completed,
whichever occurs first; provided, however, that (i) such 180-day period shall be extended for a period of time equal to the period the Holder refrains from selling any securities included in such registration at the request of an
underwriter of common stock or other securities of the Company, and (ii) in the case of any registration of Registrable Securities on Form S-3 which are intended to be offered on a continuous or delayed basis, such 180-day period shall be
extended, if necessary, to keep the registration statement effective until all such Registrable Securities are sold, provided that Rule 415, or any successor rule under the Securities Act, permits an offering on a continuous or delayed basis, and
provided further that applicable rules under the Securities Act governing the obligation to file a post-effective amendment permit, in lieu of filing a post-effective amendment which (A) includes any prospectus required by Section 10(a)(3)
of the Securities Act or (B) reflects facts or events representing a material or fundamental change in the information set forth in the registration statement, the incorporation by reference of information required to be included in
(A) and (B) above shall be contained in periodic reports filed pursuant to Section 13 or 15(d) of the Exchange Act in the registration statement; 

(b) Furnish to the Holders participating in such registration and to the underwriters of the securities being registered such reasonable
number of copies of the registration statement, preliminary prospectus, final prospectus, and such other documents as they may reasonably request in order to facilitate the public offering of such securities; 

(c) Prepare and file with the Commission such amendments and supplements to such registration statement and the prospectus used in
connection with such registration statements as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration statement; 

(d) Notify each seller of Registrable Securities covered by such registration statement at any time when a prospectus relating thereto
is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a
material fact required to be stated therein or necessary to make the statements therein not misleading or incomplete in the light of the circumstances then existing, and at the request of any such seller, prepare and furnish to such seller a
reasonable number of copies of a supplement to or an amendment of such prospectus as may be necessary so that, as thereafter delivered to the purchaser of such shares, such prospectus shall not include an untrue statement of a material fact or omit
to state a material fact required to be stated therein or necessary to make the statements therein not misleading or incomplete in the light of the circumstances then existing; 

 

 11 

 (e) Use its best efforts to register and qualify the securities covered by such
registration statement under such other securities or blue sky laws of such jurisdictions as shall be reasonably requested by the Holders, provided that the Company shall not be required in connection therewith or as a condition thereto to qualify
to do business or to file a general consent to service of process in any such states or jurisdictions; 
 (f) Cause all such
Registrable Securities to be listed on each securities exchange on which similar securities issued by the Company are then listed; 

(g) Provide a transfer agent and registrar for all Registrable Securities and a CUSIP number for all such Registrable Securities, in
each case not later than the effective date of such registration; 
 (h) Use its best efforts to furnish, at the request of any
Holder requesting registration of Registrable Securities pursuant to this Section 1, on the date that such Registrable Securities are delivered to the underwriters for sale in connection with a registration pursuant to this Section 1, if
such securities are being sold through underwriters, or, if such securities are not being sold through underwriters, on the date that the registration statement with respect to such securities becomes effective, (i) an opinion, dated such date,
of the counsel representing the Company for the purposes of such registration, in form and substance as is customarily given to underwriters in an underwritten public offering, addressed to the underwriters, if any, and to the Holders requesting
registration of Registrable Securities and (ii) a letter, dated such date, from the independent certified public accountants of the Company, in form and substance as is customarily given by independent certified public accountants to
underwriters in an underwritten public offering, addressed to the underwriters, if any, and to the Holders requesting registration of Registrable Securities (to the extent the then-applicable standards of professional conduct permit said letter to
be addressed to the Holders); 
 (i) In connection with any underwritten offering pursuant to a registration statement filed
pursuant to this Agreement, enter into and perform an underwriting agreement in form reasonably necessary to effect the offer and sale of Registrable Securities, provided such underwriting agreement contains reasonable and customary provisions, and
provided further that each Holder participating in such underwriting shall also enter into and perform its obligations under such an agreement; and 

(j) Make available for inspection by any underwriter participating in any disposition pursuant to such registration statement, and any
attorney or accountant retained by any such underwriter (collectively, the “Inspectors”), all pertinent records and documents of the Company (collectively, the “Records”) as shall be reasonably
necessary to enable them to exercise any applicable due diligence responsibility, and cause the Company’s officers, directors, and employees to use good faith to supply such information as is reasonably requested by any such Inspector to meet
such responsibilities. Records which the Company determines, in good faith, to be confidential shall not be disclosed by the Inspectors unless (i) the disclosure of such Records is necessary to avoid or correct a misstatement or omission in the
registration statement or (ii) the release of such Records is ordered pursuant to a subpoena or other order from a court of competent jurisdiction. The relevant Inspector will, upon learning that disclosure of such Records is sought in a court
of competent jurisdiction, give 
  

 12 

 
notice to the Company and allow the Company, at the Company’s expense, to undertake appropriate action to prevent disclosure of the Records deemed confidential. 

1.7 Information by Holder. The Holder or Holders of Registrable Securities included in any registration shall furnish to the
Company such information regarding such Holder or Holders, the Registrable Securities held by them, and the distribution proposed by such Holder or Holders as the Company may request in writing and as shall be required in connection with any
registration, qualification, or compliance referred to in this Section 1, and the refusal to furnish such information by any Holder or Holder shall relieve the Company of its obligations in this Section 1 with respect to such Holder or
Holders. Furthermore, the Company shall have no obligation with respect to any registration requested pursuant to Section 1.3 or Section 1.4 of this Agreement if, as a result of the application of the preceding sentence, the number of
shares or the anticipated aggregate offering price of the Registrable Securities to be included in the registration does not equal or exceed the number of shares or the anticipated aggregate offering price required to originally trigger the
Company’s obligation to initiate such registration as specified in the definition of “Initiating Holders” or “Form S-3 Initiating Holders,” whichever is applicable. 

1.8 Indemnification. 

(a) To the extent permitted by law, the Company will indemnify and hold harmless each Holder, each of its officers, directors, members,
partners, legal counsel, and accountants, and each person controlling such Holder within the meaning of Section 15 of the Securities Act, with respect to which registration, qualification, or compliance has been effected pursuant to this
Section 1, and each underwriter, if any, and each person who controls any underwriter within the meaning of Section 15 of the Securities Act, against all expenses, claims, losses, damages, or liabilities (or actions, proceedings, or
settlements in respect thereof) arising out of or based on any untrue statement (or alleged untrue statement) of a material fact contained or incorporated by reference in any registration statement, prospectus, offering circular, or other document
(including any related registration statement, notification, or the like), or any amendment or supplement thereto, incident to any such registration, qualification, or compliance, or based on any omission (or alleged omission) to state therein a
material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances in which they were made, not misleading, or any violation (or alleged violation) by the Company of the Securities Act or Exchange
Act, or any applicable state securities law, or any rule or regulation promulgated thereunder applicable to the Company in connection with any such registration, qualification, or compliance, and the Company will reimburse each such Holder, each of
its officers, directors, members, partners, legal counsel, and accountants, and each person controlling such Holder, each such underwriter and each person who controls any such underwriter, for any legal and any other expenses reasonably incurred in
connection with investigating, preparing, defending, or settling any such claim, loss, damage, liability, or action, as such expenses are incurred, provided that the Company will not be liable in any such case to the extent that any such claim,
loss, damage, liability, or expense arises out of or is based on any untrue statement or omission or alleged untrue statement or omission, made in reliance upon and in conformity with written information furnished to the Company by such Holder,
controlling person, or underwriter and stated to be specifically for use therein. It is agreed that the indemnity agreement contained in this Section 1.8 shall not apply to amounts paid in settlement

  

 13 

 
of any such loss, claim, damage, liability, or action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld or delayed). 

(b) To the extent permitted by law, each Holder will, if Registrable Securities held by such Holder are included in the securities as to
which such registration, qualification, or compliance is being effected, indemnify the Company, each of its directors, officers, partners, legal counsel, and accountants, and each underwriter, if any, of the Company’s securities covered by such
a registration statement, each person who controls the Company or such underwriter within the meaning of Section 15 of the Securities Act, and each other such Holder, each of their officers, directors, members and partners, and each person
controlling such Holder within the meaning of Section 15 of the Securities Act, against all claims, losses, damages, and liabilities (or actions in respect thereof) arising out of or based on any untrue statement (or alleged untrue statement)
of a material fact contained or incorporated by reference in any such registration statement, prospectus, offering circular, or other document, or any omission (or alleged omission) to state therein a material fact required to be stated therein or
necessary to make the statements therein not misleading, and will reimburse the Company and such Holders, directors, officers, members, partners, legal counsel, and accountants, persons, underwriters, or control persons for any legal or any other
expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability, or action, as such expenses are incurred, in each case to the extent, but only to the extent, that such untrue statement (or alleged
untrue statement) or omission (or alleged omission) is made in such registration statement, prospectus, offering circular, or other document in reliance upon and in conformity with written information furnished to the Company by such Holder and
stated to be specifically for use therein, provided, however, that the obligations of such Holder hereunder shall not apply to amounts paid in settlement of any such claims, losses, damages, or liabilities (or actions in respect thereof) if such
settlement is effected without the consent of such Holder (which consent shall not be unreasonably withheld or delayed); and provided that that in no event shall any indemnity under this Section 1.8 (when combined with any contribution under
Section 1.8(d)) exceed the net proceeds received by such Holder in such offering. 
 (c) Each party entitled to
indemnification under this Section 1.8 (the “Indemnified Party”) shall give notice to the party required to provide indemnification (the “Indemnifying Party”) promptly after such Indemnified Party
has actual knowledge of any claim as to which indemnity may be sought, and shall permit the Indemnifying Party to assume the defense of any such claim or any litigation resulting therefrom, provided that counsel for the Indemnifying Party, who shall
conduct the defense of such claim or litigation, shall be approved by the Indemnified Party (whose approval shall not unreasonably be withheld), and the Indemnified Party may participate in such defense at such party’s expense, provided
further, however, that an Indemnified Party (together with all other Indemnified Parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the reasonable fees and expenses to be paid
by the Indemnifying Party, if representation of such Indemnified Party by the counsel retained by the Indemnifying Party would be inappropriate due to actual or potential differing interests between such Indemnified Party and any other party
represented by such counsel in such proceeding; and provided further that the failure of any Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its obligations under this Section 1 unless (and only
to the extent) the failure to give such notice is materially prejudicial to an Indemnifying Party’s ability to defend 
  

 14 

 
such action. No Indemnifying Party, in the defense of any such claim or litigation, shall, except with the consent of each Indemnified Party, consent to entry of any judgment or enter into any
settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a release from all liability in respect to such claim or litigation. Each Indemnified Party shall furnish such
information regarding itself or the claim in question as an Indemnifying Party may reasonably request in writing and as shall be reasonably required in connection with the defense of such claim and litigation resulting therefrom. 

(d) If the indemnification provided for in this Section 1.8 is held by a court of competent jurisdiction to be unavailable to an
Indemnified Party with respect to any claim, loss, damage, liability, or expense referred to therein, then the Indemnifying Party, in lieu of indemnifying such Indemnified Party hereunder, shall contribute to the amount paid or payable by such
Indemnified Party as a result of such claim, loss, damage, liability, or expense in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party on the one hand and the Indemnified party on the other in connection with
the statements or omissions that resulted in such claim, loss, damage, liability, or expense, as well as any other relevant equitable considerations. The relative fault of the Indemnifying Party and of the Indemnified Party shall be determined by
reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact related to information supplied by the Indemnifying Party or by the Indemnified Party and the parties’
relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission. The Company and the Holders agree that it would not be just and equitable if contribution pursuant to this Section 1.8 were
based solely upon the number of entities from whom contribution was requested or by any other method of allocation which does not take account of the equitable considerations referred to above. In no event shall any contribution by a Holder under
this Section 1.8 (when combined with any indemnification under Section 1.8(b)) exceed the net proceeds received by such Holder in such offering. 

(e) The amount paid or payable by an Indemnified Party as a result of the losses, claims, damages, and liabilities referred to above in
this Section 1.8 shall be deemed to include any legal or other expenses reasonably incurred by such Indemnified Party in connection with investigating or defending any such action or claim, subject to the provisions of Section 1.8(c). No
person guilty of fraudulent misrepresentation (within the meaning of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. 

(f) Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting
agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

(g) The obligations of the Company and Holders under this Section 1.8 shall survive the completion of any offering of Registrable
Securities in a registration statement. 
 1.9 Expenses of Registration. All Registration Expenses shall be borne by the
Company; provided, however, that if the Holders bear the Registration Expenses for 
  

 15 

 
any registration proceeding begun pursuant to Section 1.3 and subsequently withdrawn by the Holders registering shares therein, such registration proceeding shall not be counted as a
requested registration pursuant to Section 1.3. Furthermore, in the event that a withdrawal by the Holders is based upon material adverse information relating to the Company that is different from the information known or reasonably available
(upon request from the Company or otherwise) to the Holders requesting registration at the time of their request for registration under Section 1.3, such registration proceeding shall not be counted as a requested registration pursuant to
Section 1.3, even though the Holders do not bear the Registration Expenses for such registration. All Selling Expenses relating to securities registered on behalf of the Holders shall be borne by the holders of the registered securities
included in such registration pro rata on the basis of the number of shares so registered. 
 1.10 Rule 144 Reporting.
With a view to making available the benefits of certain rules and regulations of the Commission which may at any time permit the sale of the Restricted Securities to the public without registration after such time as a public market exists for the
Common Stock of the Company, the Company agrees to use its best efforts to: 
 (a) Make and keep public information available,
as those terms are understood and defined in Rule 144, at all times after the effective date that the Company becomes subject to the reporting requirements of the Securities Act or the Exchange Act; 

(b) File with the Commission in a timely manner all reports and other documents required of the Company under the Securities Act and the
Exchange Act (at any time after it has become subject to such reporting requirements); and 
 (c) So long as a Holder owns any
Restricted Securities, to furnish to the Holder forthwith upon request a written statement by the Company as to its compliance with the reporting requirements of Rule 144 and of any other reporting requirements of the Securities Act and the Exchange
Act (at any time after it has become subject to such reporting requirements), a copy of the most recent annual or quarterly report of the Company, and such other reports and documents of the Company and other information in the possession of or
reasonably obtainable by the Company as a Holder may reasonably request in availing itself of any rule or regulation of the Commission allowing a Holder to sell any such securities without registration. 

(d) Take such action, including the voluntary registration of its Common Stock under Section 12 of the Exchange Act, as is
necessary to enable the Holders to utilize Form S-3 for the sale of their Registrable Securities, such action to be taken as soon as practicable after the end of the fiscal year in which the first registration statement filed by the Company for the
offering of its securities to the general public is declared effective. 
 1.11 Transfer of Registration Rights. The
rights to cause the Company to register securities granted to any party hereto under Section 1 may be assigned by a Holder only to a transferee or assignee of the lesser of (i) all of such Holder’s Registrable Securities and
(ii) Two Million Five Hundred Thousand (2,500,000) shares of Registrable Securities (as appropriately adjusted for stock splits and the like) or, with respect to Registrable Securities that are Series C Preferred Stock or Series D
Preferred Stock or shares of Common Stock issuable 
  

 16 

 
upon conversion of Series C Preferred Stock or Series D Preferred Stock, Five Hundred Thousand (500,000) shares (as appropriately adjusted for stock splits and the like), provided
that the Company is given written notice at the time of or promptly after said assignment, stating the name and address of the transferee or assignee and identifying the securities with respect to which such registration rights are being assigned,
and, provided further, that the assignee of such rights agree in writing to be bound by the terms and conditions of this Agreement. Notwithstanding the foregoing, no such minimum share assignment requirement shall be necessary for an
assignment by a Holder which is (A) a partnership to its partners or retired partners in accordance with partnership interests, (B) a limited liability company to its members or former members in accordance with their interest in the
limited liability company, (C) a corporation to its shareholders in accordance with their interests in the corporation, (D) to the Holder’s family member or trust for the benefit of an individual Holder, or (E) to any Affiliated
Entity. 
 1.12 Limitations on Subsequent Registration Rights. From and after the date hereof, the Company shall not,
without the prior written consent of Holders who in the aggregate hold more than sixty percent (60%) of the Common Stock then issued or issuable upon conversion of the Shares, enter into any agreement granting any holder or prospective holder
of any securities of the Company registration rights the terms of which are more favorable than the registration rights granted to holders of Shares hereunder. 

1.13 Procedure for Underwriter Cutbacks. In any circumstance in which all of the Registrable Securities and other shares of
Common Stock of the Company with registration rights that have not been expressly subordinated to the rights under this Agreement (the “Other Shares”) requested to be included in a registration pursuant to Section 1.5 on
behalf of Holders or Other Stockholders cannot be so included as a result of limitations of the aggregate number of shares of Registrable Securities and Other Shares that may be so included, the number of shares of Registrable Securities and Other
Shares that may be so included shall be allocated among the Holders and Other Stockholders requesting inclusion of shares pro rata based upon the total number of Registrable Securities or Other Shares held by such Holders and Other Stockholders,
respectively; provided, however, that such allocation shall not operate to reduce the aggregate number of Registrable Securities or Other Shares to be included in such registration if any Holder or Other Stockholder does not request
inclusion of the maximum number of shares of Registrable Securities or Other Shares allocated to such Holder or Other Stockholder pursuant to the above-described procedure, in which case the remaining portion of his allocation shall be reallocated
among those requesting Holders and Other Stockholders whose allocations did not satisfy their requests pro rata on the basis of total number of shares of Registrable Securities and Other Shares held by such Holders and Other Stockholders, and this
procedure shall be repeated until all shares of Registrable Securities and Other Shares which may be included in the registration on behalf of the Holders and Other Stockholders have been so allocated. The Company shall not limit the number of
shares of Registrable Securities to be included in a registration pursuant to Section 1.5 in order to include shares of stock issued to founders of the Company or to employees, officers, directors, or consultants pursuant to the Company’s
equity incentive plans, or to otherwise hold shares of any other stockholder that are not Other Shares. Notwithstanding the foregoing, the number of shares of Registrable Securities included in a registration pursuant to Section 1.5 of this
Agreement shall not be reduced below 
  

 17 

 
twenty five percent (25%) of the securities included in such registration unless such offering is the Qualified IPO. 

1.14 Standoff Agreement. Each Holder agrees in connection with the Company’s IPO that, upon request of the underwriters
managing such IPO, not to sell, make any short sale of, loan, pledge or otherwise hypothecate or encumber, grant any option for the purchase of, or otherwise dispose of any Registrable Securities (other than those included in the registration)
without the prior written consent of such underwriters, as the case may be, for such period of time (not to exceed one hundred eighty (180) days from the effective date of such registration (or such longer period, not to exceed 18 days after
the expiration of the 180-day period, as the underwriters or the Company shall request in order to facilitate compliance with NASD Rule 2711)) as may be requested by such managing underwriters, provided that all directors, officers and
holders of two percent (2%) or more of the Company’s outstanding capital stock are similarly bound. The Company agrees not to (and shall not permit the underwriter to) release any other stockholder from any lock up agreement or covenant
unless the Holders are also released on a proportionate basis relative to their respective ownership of securities. The obligations described in this Section 1.14 shall not apply to a registration relating solely to employee benefit plans on
Form S-1 or Form S-8 or similar forms that may be promulgated in the future, or a registration relating solely to a transaction on Form S-4 or similar forms that may be promulgated in the future. 

1.15 Termination of Rights. The rights of any particular Holder to cause the Company to register securities under Sections 1.3,
1.4, and 1.5 shall terminate with respect to such Holder upon the earlier to occur of (i) the five (5) year anniversary of the effective date of the IPO or (ii) when all Registrable Securities held by such Holder may be sold
immediately pursuant to Rule 144. 
 2. Right of First Refusal. 

2.1 Right of First Refusal. 

(a) Right of First Refusal. Subject to the terms and conditions contained in this Section 2.1, the Company hereby grants to
each Major Investor the right of first refusal to purchase their Pro Rata Portion of any New Securities which the Company may, from time to time, propose to issue and sell, provided, however, with respect to each Major Investor, that such Major
Investor continues to hold any Shares or Common Stock issued upon conversion thereof. 
 (b) Notice of Right. In the
event the Company proposes to undertake an issuance of New Securities, it shall give each Major Investor written notice of its intention, describing the type of New Securities and the price and terms upon which the Company proposes to issue the
same. Each Major Investor shall have twenty (20) days from the date of delivery of any such notice to agree to purchase up to such Major Investor’s Pro Rata Portion of such New Securities, for the price and upon the terms specified in the
notice, by delivering written notice to the Company and stating therein the quantity of New Securities to be purchased. 
  

 18 

 (c) Right of Over-Allotment. In the event that the Major Investors fail to fully
exercise the right of first refusal within such twenty- (20-) day period, each Major Investor fully exercising its right of first refusal shall be offered the right to purchase up to the remaining portion that the Major Investors failed to exercise
(the “Over-Allotment Shares”); provided, that if the Major Investors with such over-allotment right exercise such right for an aggregate number in excess of such Over-Allotment Shares, the Over-Allotment Shares shall be
allocated among them in accordance with their respective Pro Rata Portions (or in such other manner as such electing Major Investors agree). The Company will promptly notify those Major Investors fully exercising their rights of first refusal, in
writing, of the availability of Over-Allotment Shares, and each of the fully-exercising Major Investors shall have ten (10) days from the date of receipt of any such notice to agree to purchase up to such Over-Allotment Shares (subject to the
proviso in the preceding sentence). 
 (d) Lapse and Reinstatement of Right. The Company shall have sixty (60) days
following the twenty- (20-) day period described in Section 2.1(b) and the additional ten- (10-) day period described in Section 2.1(c) to sell or enter into an agreement (pursuant to which the sale of New Securities covered thereby shall
be closed, if at all, within thirty (30) days from the date of said agreement) to sell the New Securities with respect to which the Major Investors’ right of first refusal was not exercised, at a price and upon terms no more favorable to
the purchasers of such securities than specified in the Company’s notice. In the event the Company has not sold the New Securities or entered into an agreement to sell the New Securities within said sixty- (60-) day period (or sold and issued
New Securities in accordance with the foregoing within thirty (30) days from the date of said agreement), the Company shall not thereafter issue or sell any New Securities without first offering such securities to the Major Investors in the
manner provided above. 
 2.2 Assignment of Right of First Refusal. The right of first refusal granted hereunder may not
be assigned or transferred, except that: (i) such right is assignable by each Major Investor to one or more Affiliated Entities, or to any wholly-owned subsidiary or parent of, or to any corporation or entity that is, within the meaning of the
Securities Act, controlling, controlled by, or under common control with, any such Investor; and (ii) such right is assignable between and among any Major Investors. 

2.3 Termination of Right of First Refusal. The right of first refusal granted under Section 2.1 of this Agreement shall
expire upon the earlier of, and shall not be applicable to, (i) a Qualified IPO, or (ii) a Liquidation (as defined in the Restated Certificate). 

3. Affirmative Covenants of the Company. The Company hereby covenants and agrees, so long as any Major Investor holds Registrable
Securities, as follows: 
 3.1 Financial Information. The Company will furnish to such Major Investor the following
reports: 
 (a) As soon as practicable after the end of each fiscal year, and in any event within one hundred twenty
(120) days thereafter (or such longer period as is approved by the Board, including each of the Preferred Directors), audited consolidated balance sheets of the Company and its subsidiaries, if any, as of the end of such fiscal year, and

  

 19 

 
consolidated statements of income and cash flows of the Company and its subsidiaries, if any, for such year, prepared in accordance with generally accepted accounting principles consistently
applied and setting forth in each case in comparative form the figures for the previous fiscal year, all in reasonable detail and certified by independent public accountants of national standing selected by the Company; 

(b) As soon as practicable, but in any event within forty-five (45) days after the end of each quarter of each fiscal year of the
Company, unaudited consolidated balance sheets of the Company and its subsidiaries, if any, as of the end of such quarterly period, and consolidated statements of income and cash flows of the Company and its subsidiaries, if any, for such quarterly
period, prepared in accordance with generally accepted accounting principles consistently applied and setting forth in each case in comparative form the figures for the corresponding quarterly periods of the previous fiscal year and the figures
projected by the Company’s annual budget, subject to changes resulting from normal year-end audit adjustments, all in reasonable detail and certified by the principal financial or accounting officer of the Company, except such financial
statements need not contain the notes required by generally accepted accounting principles; 
 (c) As soon as practicable after
the end of each calendar month, and in any event within thirty (30) days thereafter, consolidated balance sheets of the Company and its subsidiaries, if any, as of the end of each calendar month setting forth in comparative form the results
projected by the Company’s annual budget, and consolidated statements of income and cash flow for such period and for the current fiscal year to date; 

(d) As soon as practicable after the end of each fiscal quarter, a statement showing the number of shares of each class and series of
capital stock and securities convertible into or exercisable for shares of capital stock outstanding at the end of the quarterly period, and the number of common shares issuable upon conversion or exercise of any outstanding securities convertible
or exercisable for common shares and the exchange ratio or exercise price applicable thereto, all in sufficient detail as to permit the Major Investor to calculate its percentage equity ownership in the Company. 

3.2 Operating Plan and Budget. As soon as practicable upon approval or adoption by the Board, and in any event at least thirty
(30) days prior to the end of each fiscal year, the Company will furnish the Major Investors with the Company’s budget and operating plan (including projected balance sheets and profit and loss and cash flow statements, forecasts of
revenues, expenses, significant projected milestones and projected cash position on a month-to-month basis) for the upcoming fiscal year. 

3.3 Inspection. The Company shall permit each Major Investor, at such Major Investor’s expense and upon reasonable notice
given to the Company to visit and inspect the Company’s properties, to examine its books of account and other records (and make copies and take extracts therefrom), and to discuss the Company’s affairs, finances and accounts with its
officers, all at such reasonable times as may be requested by such Major Investor. 
 3.4 Stock Vesting. All stock and
stock options issued to employees, directors, consultants and other service providers after the date of this Agreement will be subject 

 

 20 

 
to vesting at a rate of 25% one year after the vesting commencement date, with monthly vesting thereafter for the next thirty six (36) months, unless otherwise approved by the Board. Each
agreement pursuant to which such stock or stock option is issued or granted shall include a repurchase option such that, upon termination of the employee, director, consultant or other service provider, as the case may be, whether such termination
be with or without cause, the Company or its assignee (to the extent permissible under applicable securities laws) retains the option to repurchase any unvested shares held by such employee, director, consultant or other service provider at the
price such employee, director, consultant or other service provider paid for the shares. 
 3.5 Key Man Life Insurance.
The Company shall, as soon as practicable, secure a “key person” term life insurance policy from a financially sound and reputable insurer which names the Company as sole beneficiary, on such executives and on such terms, as are reasonably
acceptable to the Board. 
 3.6 Directors’ & Officers’ Liability. The Company shall purchase, within
30 days of the date of this Agreement, and maintain a policy or policies of directors’ and officers’ liability insurance (“D&O Insurance”) on terms and conditions reasonably acceptable to the Company and the
Holders who in the aggregate hold more than sixty percent (60%) of the Common Stock then issued or issuable upon conversion of the Shares. The Company shall keep such D&O Insurance in place so long as any of the Major Investors’
designees serve on the Board. In addition, the Company’s Certificate of Incorporation and Bylaws shall provide for (a) elimination of the liability of directors to the maximum extent permitted by law and (b) indemnification of
directors for acts on behalf of the Company to the maximum extent permitted by law. 
 3.7 Board Committees. The Audit
and Compensation Committees of the Board shall be composed of non-management directors. The Audit Committee shall include at least one Series A Director, the Series C Director and one Series D Director (each, as defined in the Restated Certificate),
and the Compensation Committee shall include at least one Series A Director, the Series B Director, the Series C Director and one Series D Director (as defined in the Restated Certificate). The Compensation Committee shall be responsible for
reviewing and approving all option grants. 
 3.8 Actions Requiring Board Approval. So long as shares of Preferred Stock
remain outstanding, the Company will not, without the approval of the Board (and without complying with any other approval required by the Company’s certificate of incorporation, if any): 

(a) make any loan or advance to, or own any stock or other securities of, any subsidiary or other corporation, partnership, or other
entity unless it is wholly-owned by the Company; 
 (b) make any loan or advance to any person, including any employee or
director, except advances and similar expenditures in the ordinary course of business or under the terms of a employee stock or option plan approved by the Board; 

 

 21 

 (c) guarantee any indebtedness except for trade accounts of the Company or any subsidiary
arising in the ordinary course of business; 
 (d) make any investment other than investments pursuant to a Board-approved
investment policy, including in prime commercial paper, money market funds, certificates of deposit in any United States bank having a net worth in excess of $100,000,000 or obligations issued or guaranteed by the United States of America, in each
case having a maturity not in excess of two years; 
 (e) incur any aggregate indebtedness in excess of $500,000 that is not
already included in a Board-approved budget, other than trade credit incurred in the ordinary course of business; 
 (f) enter
into or be a party to any transaction with any director, officer or employee of the Company or any “associate” (as defined in Rule 12b-2 promulgated under the Exchange Act) of any such person except compensation paid in the ordinary course
of business or transactions resulting in payments to or by the Company in an amount less than $60,000 per year; 
 (g) hire,
fire or change the compensation of the executive officers, including approving any equity incentive compensation or any severance or change of control arrangements; 

(h) change the principal business of the Company, enter new lines of business or exit the current line of business; or 

(i) sell, transfer, license, pledge or encumber technology or intellectual property, other than licenses granted in the ordinary course
of business. 
 3.9 Debt Offerings. If the Company elects to raise capital through a debt offering, including the
issuance of bonds or establishment of a loan, the Company shall provide written notice to Highland of the Company’s decision to raise capital in this manner and Highland shall have thirty (30) days from delivery of such notice to elect to
provide financing for the Company; provided, however, that the financing shall be on terms acceptable to the Company in the Company’s sole discretion. 

3.10 Actions Requiring a Waiver of the Preferred. So long as shares of Preferred Stock remain outstanding, unless waived by the
holders of at least sixty percent (60%) of the then outstanding Preferred Stock, the Company will: 
 (a) maintain its
corporate existence and good standing; 
 (b) pay all taxes when due, including withholding taxes, except for such taxes being
contested in good faith by appropriate proceedings; 
 (c) promptly provide each Major Investor with written notice of any
claim made or threatened in writing by any third party with potential liability in excess of $250,000; and 
  

 22 

 (d) maintain commercially reasonable general liability, casualty and product liability
insurance. 
 3.11 Company Confidential Information. Notwithstanding anything to the contrary in this Section 3, no
Holder by reason of this Agreement shall have access to any trade secrets or classified information of the Company. Each Holder agrees to hold in confidence and trust and not to misuse or disclose any confidential information provided pursuant to
this Section 3. The Company shall not be required to comply with this Section 3 in respect of any Holder whom the Company reasonably determines to be a competitor or an officer, employee, director, or greater than ten percent
(10%) stockholder of a competitor. Notwithstanding the foregoing, no information which is confidential or proprietary in nature shall be disclosed to Genentech, Inc. (“Genentech”) pursuant to this Agreement. Any
confidential or proprietary information disclosed to Genentech shall be disclosed pursuant to a separate confidential disclosure agreement signed by the Company and Genentech. 

3.12 Observer Rights. 

(a) Until August 10, 2010, provided Essex or its affiliate continues to hold shares of Series D Preferred, the Company shall allow
one individual designated by Essex or its affiliate to attend all meetings of its Board in a nonvoting observer capacity (the “Essex Representative”), and, in connection therewith, shall give the Essex Representative copies
of all notices, minutes, consents and other materials that it provides to its directors at the same time and in the same manner as provided to such directors. The Essex Representative shall agree to hold in confidence and trust and to act in a
fiduciary manner with respect to all such materials and all information it obtains at each such meeting and the Company reserves the right to withhold any materials and information and to exclude the Essex Representative from any meeting or portion
thereof if the Company or the Board believes that such withholding or exclusion is reasonably necessary (i) to preserve the attorney-client privilege, (ii) to protect highly confidential and proprietary information, (iii) to preserve
any fiduciary obligations of the Board, (iv) to prevent any conflict of interest, (v) to protect information regarding potential or actual strategic investments or partnerships with a commercial entity or (vi) for other similar
reasons. The Company shall not be required to comply with the provisions of this Section 3.12(a) if Essex or the Essex Representative becomes a holder of more than five percent (5%) of the outstanding securities of a competitor of the
Company or if the Essex Representative becomes an officer, employee or director of a competitor of the Company. 
 (b) As long
as OrbiMed or its affiliate continues to hold at least fifty percent (50%) of the Series D Preferred issued by the Company to OrbiMed pursuant to the Series D Agreement, the Company shall allow one individual designated by OrbiMed or its
affiliate to attend all meetings of its Board in a nonvoting observer capacity (the “OrbiMed Representative”), and, in connection therewith, shall give the OrbiMed Representative copies of all notices, minutes, consents and
other materials that it provides to its directors at the same time and in the same manner as provided to such directors. The OrbiMed Representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all such
materials and all information it obtains at each such meeting and the Company reserves the right to withhold any materials and information and to exclude the OrbiMed Representative from any meeting or portion thereof if the Company or the Board
believes that such withholding or 
  

 23 

 
exclusion is reasonably necessary (i) to preserve the attorney-client privilege, (ii) to protect highly confidential and proprietary information, (iii) to preserve any fiduciary
obligations of the Board, (iv) to prevent any conflict of interest, (v) to protect information regarding potential or actual strategic investments or partnerships with a commercial entity or (vi) for other similar reasons. The Company
shall not be required to comply with the provisions of this Section 3.12(b) if OrbiMed or the OrbiMed Representative becomes a holder of more than five percent (5%) of the outstanding securities of a competitor of the Company or if the
OrbiMed Representative becomes an officer, employee or director of a competitor of the Company. 
 (c) As long as Highland
continues to hold at least fifty percent (50%) of the Series C Preferred held by Highland at the Closing (as defined in the Series D Agreement), the Company shall allow one individual designated by Highland to attend all meetings of its Board
in a nonvoting observer capacity (the “Highland Representative”), and, in connection therewith, shall give the Highland Representative copies of all notices, minutes, consents and other materials that it provides to its
directors at the same time and in the same manner as provided to such directors. The Highland Representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all such materials and all information it
obtains at each such meeting and the Company reserves the right to withhold any materials and information and to exclude the Highland Representative from any meeting or portion thereof if the Company or the Board believes that such withholding or
exclusion is reasonably necessary (i) to preserve the attorney-client privilege, (ii) to protect highly confidential and proprietary information, (iii) to preserve any fiduciary obligations of the Board, (iv) to prevent any
conflict of interest, (v) to protect information regarding potential or actual strategic investments or partnerships with a commercial entity or (vi) for other similar reasons. The Company shall not be required to comply with the
provisions of this Section 3.12(c) if Highland or the Highland Representative becomes a holder of more than five percent (5%) of the outstanding securities of a competitor of the Company or if the Highland Representative becomes an
officer, employee or director of a competitor of the Company. 
 3.13 Termination of Covenants. The covenants set forth
in this Section 3 shall terminate and be of no further force or effect after the earlier of (i) the date on which the Company is required to file reports with the Commission pursuant to Section 13 or 15(d) of the Exchange Act and
(ii) the occurrence of any of the events specified in Section 2.3 hereof; provided, that the covenants set forth in Section 3.6 shall not terminate so long as any Major Investor’s designee serves on the Board. 

4. Acknowledgement. The Company hereby acknowledges that one (1) or more of the directors nominated to serve on the Board by
the Investors (each, a “Fund Director”) may have certain rights to indemnification, advancement of expenses and/or insurance provided by one or more of the Investors and certain of their affiliates (collectively, the “Fund
Indemnitors”). The Company hereby agrees (a) that it is the indemnitor of first resort (that is, its obligations to any such Fund Director are primary and any obligation of the Fund Indemnitors to advance expenses or to provide
indemnification for the same expenses or liabilities incurred by such Fund Director are secondary), (b) that it shall be required to advance the full amount of expenses incurred by such Fund Director and shall be liable for the full amount of
all expenses, judgments, penalties, fines and amounts paid in settlement by or on behalf of any such Fund Director to the extent legally permitted and as required by the Restated Certificate or Bylaws of

  

 24 

 
the Company (or any agreement between the Company and such Fund Director), without regard to any rights such Fund Director may have against the Fund Indemnitors, and (c) that it irrevocably
waives, relinquishes and releases the Fund Indemnitors from any and all claims against the Fund Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment
by the Fund Indemnitors on behalf of any such Fund Director with respect to any claim for which such Fund Director has sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a right of contribution
and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of such Fund Director against the Company. 

5. Miscellaneous. 

5.1 Governing Law. This Agreement shall be governed in all respects by the laws of the State of California without regard to
choice of laws or conflict of laws provisions thereof. 
 5.2 Successors and Assigns. Except as otherwise provided
herein, the provisions hereof shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors, and administrators of the parties hereto. Nothing in this Agreement, express or implied, is intended to confer upon any
party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided by this Agreement. 

5.3 Entire Agreement. This Agreement and the other documents delivered pursuant hereto constitute the full and entire
understanding and agreement among the parties with regard to the subjects hereof and thereof. Subject to the provisions of Section 5.10 below, neither this Agreement nor any term hereof may be amended, waived, discharged or terminated other
than by a written instrument signed by the party against whom enforcement of any such amendment, waiver, discharge or termination is sought, unless otherwise provided. 

5.4 Notices. All notices and other communications required or permitted hereunder shall be in writing and shall be mailed
by registered mail, certified mail (return receipt requested) or by internationally recognized express courier (e.g., Federal Express), postage prepaid, or sent by fax or otherwise delivered by hand or by messenger addressed: 

(a) If to an Investor, at the Investor’s address or fax number set forth beneath such Investor’s signature hereto, or at such
other address as such Investor shall have furnished to the Company; 
 (b) If to the Company, one copy should be sent to its
address or fax number of record and addressed to the attention of the President, or at such other address or fax number as the Company shall have furnished to the parties hereto, with copies to Alan C. Mendelson and Greg Chin, Latham &
Watkins LLP, 140 Scott Drive, Menlo Park, California 94025, (fax) 650-463-2600; and 
  

 25 

 (c) Each such notice shall for all purposes of this Agreement be treated as effective or
having been given on the earliest to occur of the following: 
 (i) The date of personal delivery or delivery by messenger;

 (ii) One (1) business day after transmission by fax, with confirmation of transmission; 

(iii) One (1) business day after deposit with an internationally recognized express courier for United States deliveries, or three
(3) business days after such deposit for deliveries outside of the United States; or 
 (iv) Three (3) business days
after deposit in a regularly maintained receptacle for the deposit of the United Stated mail be registered or certified mail (return receipt requested) for United States deliveries. 

5.5 Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing to any Holder upon any breach or
default of the Company under this Agreement shall impair any such right, power, or remedy of such party, nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default
thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent, or approval of any kind or character on the part of any
party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing or as
provided in this Agreement. All remedies, either under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 

5.6 Dispute Resolution Fees. If any action at law or in equity is necessary to enforce or interpret the terms of this Agreement,
the prevailing party shall be entitled to reasonable attorney’s fees, costs, and disbursements in addition to any other relief to which such party may be entitled. 

5.7 Counterparts. This Agreement may be executed in any number of counterparts and signatures may be delivered by facsimile, each
of which may be executed by less than all parties, each of which shall be enforceable against the parties actually executing such counterparts, and all of which together shall constitute one instrument. 

5.8 Severability. If any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be illegal,
unenforceable, or void, portions of such provision, or such provision in its entirety, to the extent necessary, shall be severed from this Agreement and the balance of this Agreement shall be enforceable in accordance with its terms. 

 

 26 

 5.9 Titles and Subtitles. The titles and subtitles used in this Agreement are used
for convenience only and are not to be considered in construing or interpreting this Agreement. 
 5.10 Amendment and
Waiver. Any provision of this Agreement may be amended or waived (either generally or in a particular instance and either retroactively or prospectively) only with the written consent of the Company and a Holder or Holders holding, in the
aggregate, more than sixty percent (60%) of the outstanding shares of Common Stock issued or issuable pursuant to conversion of the Shares. Any amendment or waiver effected in accordance with this paragraph shall be binding upon each Holder and
the Company; provided, however, that any amendment that would materially and adversely affect the rights of, or impose additional material obligations on, any Holder or groups of Holders in a manner different than the other Holders shall not be
effective against such affected Holder without the written consent of such Holder. In addition, except as provided in Section 1.14 above, the Company may waive performance of any obligation owing to it, as to some or all of the Holders, or
agree to accept alternatives to such performance, without obtaining the consent of any Holder. Notwithstanding anything to the contrary herein, if the Company shall issue additional shares of Series D Preferred pursuant to the Purchase Agreement,
any purchaser of such shares of Series D Preferred may become a party to this Agreement by delivering an executed counterpart signature page to the Company and such purchaser shall be deemed an “Investor” hereunder, all without the
requirement of any consent from any party hereunder or amendment or waiver hereof. 
 5.11 Effect of Amendment or
Waiver. The Holders and their successors and assigns acknowledge that by the operation of Section 5.10 hereof Holders holding more than sixty percent (60%) of the outstanding shares of Common Stock issued or issuable pursuant to
conversion of the Shares, acting in conjunction with the Company, will have the right and power to diminish or eliminate any or all rights pursuant to this Agreement. 

5.12 Termination of Prior Agreement. The Prior Agreement is hereby amended and restated in full to read as set forth herein.

 5.13 Waiver. The Investors who were party to the Prior Agreement and who were “Major Investors” as defined
in the Prior Agreement hereby waive any and all right of first refusal and notice requirements set forth in Section 2.1 of the Prior Agreement with respect to the issuance of the Series D Preferred Stock pursuant to the Purchase Agreement. The
Investors who were party to the Prior Agreement also hereby consent to the registration rights granted herein as required by Section 1.12 of the Prior Agreement. 

5.14 Rights of Investors. Each party to this Agreement shall have the absolute right to exercise or refrain from exercising any
right or rights that such party may have by reason of this Agreement, including, without limitation, the right to consent to the waiver or modification of any obligation under this Agreement, and such party shall not incur any liability to any other
party or other holder of any securities of the Company as a result of exercising or refraining from exercising any such right or rights. 

5.15 Aggregation of Stock. All shares of Preferred Stock and Common Stock of the Company held or acquired by affiliated entities
or persons (including those held by 
  

 27 

 
Affiliated Entities) shall be aggregated for the purpose of determining the availability of any rights under this Agreement. 

5.16 Specific Performance. The rights of the parties under this Agreement are unique and, accordingly, the parties shall, in
addition to such other remedies as may be available to any of them at law or in equity, have the right to enforce their rights hereunder by actions for specific performance to the extent permitted by law. 

5.17 Jurisdiction and Venue; Waiver of Jury Trial. Any action, suit or proceeding arising out of or relating to this Agreement
shall be brought in the state courts of the State of California located in Santa Clara County, or, if it has or can acquire jurisdiction, any Federal court located in such State and County, and EACH OF THE PARTIES HERETO, AFTER CONSULTING WITH OR
HAVING HAD THE OPPORTUNITY TO CONSULT WITH COUNSEL, HEREBY KNOWINGLY, VOLUNTARILY, INTENTIONALLY AND IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF SUCH COURTS AND WAIVES TRIAL BY JURY, IN EACH CASE IN CONNECTION WITH ANY ACTION, SUIT OR
PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT. Each of the parties hereto hereby irrevocably and unconditionally waives any objection to the laying of venue of any action, suit or proceeding arising out of or relating to this Agreement or
the transactions contemplated hereby in the courts of the State of California or the United States of America, in each case located in Santa Clara County, and hereby further irrevocably and unconditionally waives and agrees not to plead or claim in
any such court that any such matter brought in any such court has been brought in an inconvenient forum. 
 [THIS SPACE LEFT
BLANK INTENTIONALLY] 
  

 28 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first
above written. 
  

			
	COMPLETE GENOMICS, INC.
		
	By:	 	        /s/ Clifford A. Reid            
		 	Clifford A. Reid, President and
		 	Chief Executive Officer
		
		 	Company Address:
		
		 	2071 Stierlin Court
		 	Mountain View, CA 94043

  

 SIGNATURE PAGE TO THE THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

 Investors: 
  

									
		 	ESSEX WOODLANDS HEALTH VENTURES FUND VIII, L.P.
			
		 	By: 	  	ESSEX WOODLANDS HEALTH VENTURES VIII, L.P.
 Its General Partner

				
		 		  	By:	  	 ESSEX WOODLANDS HEALTH VENTURES VIII, LLC

Its General Partner

					
		 		  		  	By:	  	    /s/Jeff
Himawan                                
		 		  		  	Name:	  	      Jeff
Himawan                                    
		 		  		  	Title:	  	Manager
			
		 	Address:	  	335 Bryant Street
				
		 		  		  	Palo Alto, CA 94301
		 		  		  	Attn: Jeff Himawan
			
		 	Fax No:	  	(650) 327-9755
		
		 	ESSEX WOODLANDS HEALTH VENTURES FUND VIII-A, L.P.
			
		 	By:	  	ESSEX WOODLANDS HEALTH VENTURES VIII, L.P.
 Its General Partner

				
		 		  	By:	  	 ESSEX WOODLANDS HEALTH VENTURES VIII, LLC

Its General Partner

					
		 		  		  	By:	  	    /s/Jeff
Himawan                                
		 		  		  	Name:	  	      Jeff
Himawan                                    
		 		  		  	Title:	  	Manager
			
		 	Address:	  	335 Bryant Street
		 		  		  	Palo Alto, CA 94301
		 		  		  	Attn: Jeff Himawan
		 	Fax No:	  	(650) 327-9755

  

 SIGNATURE PAGE TO THE THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

 Investors: 
  

									
		  	ESSEX WOODLANDS HEALTH VENTURES FUND VIII-B, L.P.
			
		  	By:
	  	ESSEX WOODLANDS HEALTH VENTURES VIII, L.P.
 Its General Partner

				
		  		  	By:	  	ESSEX WOODLANDS HEALTH VENTURES VIII, LLC
 Its General Partner

					
		  		  		  	By:	  	    /s/Jeff
Himawan                                
		  		  		  	Name:	  	      Jeff
Himawan                                    
		  		  		  	Title:	  	Manager
			
		  	Address:	  	335 Bryant Street
		  		  		  	Palo Alto, CA 94301
		  		  		  	Attn: Jeff Himawan
		  	Fax No:	  	(650) 327-9755

  

 SIGNATURE PAGE TO THE THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

 Investors: 

 

  

			
	ORBIMED ASSOCIATES III, LP
		
	By:	 	        /s/ Carl Gordon            
		 	Carl Gordon
		 	General Partner
	
	Address: 767 Third Avenue,
30th Floor
	New York, NY 10017
	
	CADUCEUS PRIVATE INVESTMENTS III, LP
		
	By:	 	        /s/ Carl Gordon            
		 	 Carl Gordon
 General Partner

	
	Address: 767 Third Avenue,
30th Floor
	New York, NY 10017

  

 SIGNATURE PAGE TO THE THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

 Investors: 

 

					
		  	HIGHLAND CRUSADER OFFSHORE PARTNERS, L.P.
		  	 By: Highland Crusader Fund GP, L.P.

		  	Its: General Partner
		  	By: Highland Crusader GP, LLC.
		  	By: Highland Capital Management, L.P.
		  	Its: Sole Member
		  	By: Strand Advisors, Inc.
		  	Its: General Partner
		
		  	
                /s/ Jason
Post

		  	Name:	 	Jason Post
		  	Title:	 	Operations Director
		
		  	HIGHLAND CREDIT OPPORTUNITIES CDO L.P.
		  	By: Highland Credit Opportunities CDO GP, L.P.
		  	Its: General Partner
		  	By: Highland Credit Opportunities CDO GP, LLC
		  	Its: General Partner
		  	By: Highland Capital Management, L.P.
		  	Its: Sole Member
		  	By: Strand Advisors, Inc.
		  	Its: General Partner
		
		  	
                /s/ Jason
Post

		  	Name:	 	Jason Post
		  	Title:	 	Operations Director

  

 SIGNATURE PAGE TO THE THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

 Investors: 

 

			
	OVP Venture Partners VI, L.P.
	By:	 	OVMC VI, LLC, as General Partner
		
	By:	 	             /s/ Chad
Waite

		 	Managing Member or Attorney In Fact
		
	Address:	 	        1010 Market Street
		 	        Kirkland WA 98033
	
	OVP VI Entrepreneurs Fund, L.P.
	By: OVMC VI, LLC, as General Partner
		
	By:	 	             /s/ Chad
Waite

		 	Managing Member or Attorney In Fact
		
	Address:	 	        1010 Market Street
		 	        Kirkland WA 98033

  

 SIGNATURE PAGE TO THE THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

 Investors: 

 

			
	Enterprise Partners VI, LP
	By:	 	Enterprise Management Partners VI, LLC as General Partner
		
		 	             /s/ Andrew E.
Senyei

	By:	 	Andrew E. Senyei
		 	Managing Director
		
	Address:	 	        2223 Avenida de la Playa
		 	        Suite 300
		 	        La Jolla CA 92037
	
	 Enterprise Partners V, LP

	By:	 	Enterprise Management Partners VI, LLC as General Partner
	
	
                /s/ Andrew E.
Senyei

	By:	 	Andrew E. Senyei
		 	Managing Director
		
	Address:	 	        2223 Avenida de la Playa
		 	        Suite 300
		 	        La Jolla CA 92037

  

 SIGNATURE PAGE TO THE THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

 Investors: 

 

  

			
	Prospect Venture Partners III, L.P.
		
	By:	 	Prospect Management Co. III, L.L.C.
	Its:	 	General Partner
	
	         /s/ Alex
Barkas                        

	Name:	 	
	Title:	 	Managing Director
	Address:	 	

  

 SIGNATURE PAGE TO THE THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

 Investors: 

 

  

			
	Aquilo Partners, L.P.
		
	By:	 	
	Its:	 	
	
	             /s/ James F. Zanze

	Name:	 	James F. Zanze
	Title:	 	Managing Director
	
	Address:

  

 SIGNATURE PAGE TO THE THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

 Investors: 

 

  

			
	The Mendelson Family Trust
	
	        /s/ Alan C.
Mendelson                
	By:	 	Alan C. Mendelson
	Title:	 	Trustee
	Address:	 	    76 De Bell Drive
		 	    Atherton, CA 94027
	
	VP Company Investments 2004, LLC
	
	        /s/ Alan C.
Mendelson                
	By:	 	Alan Mendelson
	Title:	 	Managing Member
	Address:	 	    555 West Fifth Street
		 	    Suite 80
		 	    Los Angeles, CA 90013
	
	VP Company Investments 2008, LLC
	
	        /s/ Alan C.
Mendelson                
	By:	 	Alan Mendelson
	Title:	 	Managing Member
	Address:	 	    555 West Fifth Street
		 	    Suite 80
		 	    Los Angeles, CA 90013

  

 SIGNATURE PAGE TO THE THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

 Investors: 

 

  

			
	Gold Hill Venture Lending 03 LP
	By:	 	Gold Hill Venture Lending Partners 03, LP
	Its:	 	General Partner
	
	        /s/ Tim McDonough                

	By:	 	Tim McDonough
	Title:	 	Principal, Gold Hill Capital

  

 SIGNATURE PAGE TO THE THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

 Investors: 

 

  

			
	Genentech, Inc.
		
	By:	 	
	Its:	 	
	
	        /s/ Robert
Andreatta                                    
	Name: Robert Andreatta
	Title: Vice President, Controller & Chief Accounting Officer
	
	Address:
	 1 DNA Way
 South
San Francisco, CA 94080

  

 SIGNATURE PAGE TO THE THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

 Investors: 

 

  

	
	        /s/ C. Thomas Caskey        
	C. Thomas Caskey, M.D.
	
	Address:
	Essex Woodlands Health Ventures
	1825 Pressler Street
	Suite 205
	Houston, TX 77030

  

 SIGNATURE PAGE TO THE THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

 Investors: 

 

	
	Enterprise Partners Management, LLC
	
	            /s/ Andrew E.
Senyei                                        

	Andrew E. Senyei
	As sole Director of Andrew E. Senyei, Inc.
	Manager of Enterprise Partners Management, LLC
	
	Address:
	2223 Avenida de la Playa
	La Jolla CA 92037

  

 SIGNATURE PAGE TO THE THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

 Founders: 

 

	
	 THE CURSON FAMILY LIVING TRUST

DATED JULY 30, 2001

	
	            /s/ Robert John
Curson                                
	Robert John Curson, Trustee
	Address:
	 135 Ponderosa Drive
 Santa
Cruz, CA 95060

	
	DRMANAC FAMILY TRUST DATED JUNE 21, 2000
	
	            /s/ Radoje
Drmanac                                        

	Radoje Drmanac, Trustee
	Address:
	 27635 Red Rock Road
 Los Altos
Hills, CA 94022

	
	 CLIFFORD A. REID LIVING TRUST, DATED

SEPTEMBER 3, 1997

	
	            /s/ Clifford A.
Reid                                        

	Clifford A. Reid, Trustee
	Address:
	 151 Blackburn Terrace

Pacifica, CA 94044

  

 SIGNATURE PAGE TO THE THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

 Founders: 

 

  

	
	ROBERT JOHN CURSON
	
	                 /s/
Robert John Curson

	
	Address:
	 135 Ponderosa Drive
 Santa
Cruz, CA 95060

	
	RADOJE DRMANAC
	
	                 /s/
Radoje Drmanac

	
	Address:
	 27635 Red Rock Road
 Los Altos
Hills, CA 94022

	
	CLIFFORD A. REID
	
	                 /s/
Clifford A. Reid

	
	Address:
	 151 Blackburn Terrace

Pacifica, CA 94044

  

 SIGNATURE PAGE TO THE THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

 Callida: 

 

	
	CALLIDA GENOMICS, INC.
	
	             /s/ Radoje
Drmanac

	Address: 750 N. Pastoria Ave
	Sunnyvale, CA 94085

  

 SIGNATURE PAGE TO THE THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

 EXHIBIT A 

SCHEDULE OF INVESTORS 

Essex Woodlands Health Ventures Fund VIII, L.P. 

Essex Woodlands Health Ventures Fund VIII -A, L.P. 

Essex Woodlands Health Ventures Fund VIII-B, L.P. 

OrbiMed Associates III, LP 
 Caduceus Private
Investments III, LP 
 Highland Crusader Offshore Partners, L.P. 

Highland Credit Opportunities CDO, L.P. 
 OVP
Venture Partners VI, L.P. 
 OVP VI Entrepreneurs Fund L.P. 

Enterprise Partners VI, LP 
 Enterprise Partners
V, L.P. 
 Aquilo Partners, L.P. 

Prospect Venture Partners III, L.P. 
 The
Mendelson Family Trust 
 VP Company Investments 2004, LLC 

VP Company Investments 2008, LLC 
 Gold Hill
Venture Lending 03, LP 
 Genentech, Inc. 

C. Thomas Caskey, M.D. 
 Enterprise Partners
Management, LLC 

 EXHIBIT B 

SCHEDULE OF FOUNDERS 

The Curson Family Living Trust Dated July 30, 2001 

Drmanac Family Trust Dated June 21, 2000 

Clifford A. Reid Living Trust, Dated September 3, 1997 

Robert John Curson 
 Radoje Drmanac 

Clifford A. Reid 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	 	  	Page
			
	1.	 	 Restrictions on Transferability; Registration Rights
	  	1
				
		 	1.1	  	Certain Definitions	  	1
		 	1.2	  	Restrictions	  	5
		 	1.3	  	Requested Registration	  	6
		 	1.4	  	Registration on Form S-3	  	8
		 	1.5	  	Company Registration	  	10
		 	1.6	  	Registration Procedures	  	11
		 	1.7	  	Information by Holder	  	13
		 	1.8	  	Indemnification	  	13
		 	1.9	  	Expenses of Registration	  	15
		 	1.10	  	Rule 144 Reporting	  	16
		 	1.11	  	Transfer of Registration Rights	  	16
		 	1.12	  	Limitations on Subsequent Registration Rights	  	17
		 	1.13	  	Procedure for Underwriter Cutbacks	  	17
		 	1.14	  	Standoff Agreement	  	18
		 	1.15	  	Termination of Rights	  	18
			
	2.	 	 Right of First Refusal
	  	18
				
		 	2.1	  	Right of First Refusal	  	18
		 	2.2	  	Assignment of Right of First Refusal	  	19
		 	2.3	  	Termination of Right of First Refusal	  	19
			
	3.	 	 Affirmative Covenants of the Company
	  	19
				
		 	3.1	  	Financial Information	  	19
		 	3.2	  	Operating Plan and Budget	  	20
		 	3.3	  	Inspection	  	20
		 	3.4	  	Stock Vesting	  	20
		 	3.5	  	Key Man Life Insurance	  	21
		 	3.6	  	Directors’ & Officers’ Liability	  	21
		 	3.7	  	Board Committees	  	21
		 	3.8	  	Actions Requiring Board Approval	  	21
		 	3.9	  	Debt Offerings	  	22
		 	3.10	  	Actions Requiring a Waiver of the Preferred	  	22
		 	3.11	  	Company Confidential Information	  	23
		 	3.12	  	Observer Rights	  	23
		 	3.13	  	Termination of Covenants	  	24
			
	4.	 	 Acknowledgement
	  	24

  

 i 

							
	5.	 	 Miscellaneous
	  	25
				
		 	5.1	  	Governing Law	  	25
		 	5.2	  	Successors and Assigns	  	25
		 	5.3	  	Entire Agreement	  	25
		 	5.4	  	Notices	  	25
		 	5.5	  	Delays or Omissions	  	26
		 	5.6	  	Dispute Resolution Fees	  	26
		 	5.7	  	Counterparts	  	26
		 	5.8	  	Severability	  	26
		 	5.9	  	Titles and Subtitles	  	27
		 	5.10	  	Amendment and Waiver	  	27
		 	5.11	  	Effect of Amendment or Waiver	  	27
		 	5.12	  	Termination of Prior Agreement	  	27
		 	5.13	  	Waiver.	  	27
		 	5.14	  	Rights of Investors	  	27
		 	5.15	  	Aggregation of Stock	  	27
		 	5.16	  	Specific Performance	  	28
		 	5.17	  	Jurisdiction and Venue; Waiver of Jury Trial	  	28

 EXHIBIT A - Schedule of Investors

 EXHIBIT B - Schedule of Founders 

 OMNIBUS AMENDMENT 

This Omnibus Amendment, dated as of November 6, 2009 (this “Omnibus Amendment”) amends (i) that certain Third
Amended and Restated Investor Rights Agreement, dated as of August 12, 2009, among Complete Genomics, Inc., a Delaware corporation (the “Company”), the Investors (as defined therein) and the Founders (as defined therein)
(“the “IRA”), (ii) that certain Third Amended and Restated Right of First Refusal and Co-Sale Agreement, dated as of August 12, 2009, among the Investors (as defined therein), the Founders (as defined therein) and the
Company (the “ROFR Agreement”) and (iii) that certain Third Amended and Restated Voting Agreement, dated as of August 12, 2009, among the Company and the Stockholders (as defined therein) (the “Voting
Agreement” together with the IRA and the ROFR Agreement, the “Agreements”). 
 RECITALS 

 WHEREAS: In connection with the Company’s proposed 30:1 reverse stock split, the undersigned signatories
wish to amend the Agreements to clarify certain provisions of the Agreements; 
 WHEREAS: Section 5.10 of the
IRA provides that the IRA may be amended with the written consent of the Company and Holders (as defined therein) of more than sixty percent (60%) of the outstanding shares of Common Stock issued or issuable pursuant to conversion of the Shares
(as defined therein) (the “IRA Amendment Threshold”); 
 WHEREAS: Section 10.10 of the ROFR
Agreement provides that the ROFR Agreement may be amended with the written consent of the Company, the Significant Common Stock Holders (as defined therein) holding, in the aggregate, a majority of the outstanding shares held by all Significant
Common Stock Holders and any individual Investor (as defined therein) or group of Investors holding, in the aggregate, more than sixty percent (60%) of the common stock issued or issuable upon conversion of the Preferred Stock held by all
Investors (the “ROFR Agreement Amendment Threshold”); 
 WHEREAS: Section 10.9 of the Voting
Agreement provides that the Voting Agreement may be amended with the written consent of the Company, the holders of at least a majority of the outstanding Common Stock of the Company and the holders of at least sixty percent (60%) of the
outstanding Preferred Stock of the Company and that any amendment or waiver of Section 2.1 of the Voting Agreement shall additionally require the consent of the Director Designator(s) (as defined therein) affected by such amendment or waiver;
(the “Voting Agreement Amendment Threshold”); and 
 WHEREAS: The undersigned meet each of
the IRA Amendment Threshold, the ROFR Agreement Amendment Threshold and the Voting Agreement Amendment Threshold. 
 NOW,
THEREFORE: In consideration of the mutual promises and covenants set forth herein, and other consideration, the receipt and adequacy of which is hereby acknowledged, the parties hereto agree as follows: 

 1. IRA Amendments. 

1.1 Section 1.1 of the IRA is hereby amended to add the following definition: 

““Restated Certificate” means the Company’s Fifth Restated Certificate of Incorporation, as may be
amended from time to time.” 
 1.2 Section 1.11 of the IRA is hereby deleted in its entirety and replaced with the
following: 
 “1.11 TRANSFER OF REGISTRATION RIGHTS. The rights to cause the Company to register securities granted
to any party hereto under Section 1 may be assigned by a Holder only to a transferee or assignee of the lesser of (i) all of such Holder’s Registrable Securities and (ii) Eighty-Three Thousand Three Hundred Thirty-Three
(83,333) shares of Registrable Securities (as appropriately adjusted for stock splits and the like; provided that no adjustment shall be made with respect to the reverse stock split occurring upon filing of the Restated Certificate) or,
with respect to Registrable Securities that are Series C Preferred Stock or Series D Preferred Stock or shares of Common Stock issuable upon conversion of Series C Preferred Stock or Series D Preferred Stock, Sixteen Thousand Six Hundred Sixty-Seven
(16,667) shares (as appropriately adjusted for stock splits and the like provided that no adjustment shall be made with respect to the reverse stock split occurring upon filing of the Restated Certificate), provided that the
Company is given written notice at the time of or promptly after said assignment, stating the name and address of the transferee or assignee and identifying the securities with respect to which such registration rights are being assigned, and,
provided further, that the assignee of such rights agree in writing to be bound by the terms and conditions of this Agreement. Notwithstanding the foregoing, no such minimum share assignment requirement shall be necessary for an
assignment by a Holder which is (A) a partnership to its partners or retired partners in accordance with partnership interests, (B) a limited liability company to its members or former members in accordance with their interest in the
limited liability company, (C) a corporation to its shareholders in accordance with their interests in the corporation, (D) to the Holder’s family member or trust for the benefit of an individual Holder, or (E) to any Affiliated
Entity.” 
 2. ROFR Amendment. 

2.1. Section 8 of the ROFR Agreement is hereby deleted in its entirety and replaced with the following: 

“8. Termination. This Agreement shall terminate upon the earliest to occur of any one of the following events: (i) a
Liquidation (as defined in the Company’s Fifth Restated Certificate of Incorporation (the “Restated Certificate”)); (ii) the execution by the Company of a general assignment for the benefit of creditors or the
appointment of a receiver or trustee to take possession of the property and assets of the Company or (iii) a Qualified IPO (as defined in the Restated Certificate).” 

2.2. Exhibits A and B of the ROFR Agreement is hereby deleted in their entirety and replaced with the exhibit attached
hereto as Exhibits A and B. 
  

 - 2 - 

 3. Voting Agreement Amendment. 

3.1 Section 2.1 of the Voting Agreement is hereby deleted in its entirety and replaced with the following: 

“2.1 Two (2) members of the Board designated by the holders of the Series D Preferred, one of which shall be designed by Essex
Woodlands Health Ventures Fund VIII, L.P. and its affiliates (“Essex”) and of which the other shall be designated by OrbiMed Associates III, LP and its affiliates (“OrbiMed”) as the Series D Directors
(as defined in the Company’s Fifth Restated Certificate of Incorporation (the “Restated Certificate”). The initial designee of Essex shall be C. Thomas Caskey, M.D. The initial designee of OrbiMed shall be Carl Gordon,
Ph.D;” 
 4. Merger. Except as expressly amended above, the IRA, the ROFR Agreement and the Voting Agreement shall
remain in full force and effect. 
 5. Counterparts. This Omnibus Amendment may be executed in any number of
counterparts, each of which shall be enforceable against the parties actually executing such counterparts, and all of which together shall constitute one instrument. 

6. Governing Law. This Omnibus Amendment shall be construed and interpreted in accordance with and be governed by the laws of the
State of California without giving effect to any conflict of laws principles that would result in the application of the laws of any state other than the State of California. 

[Signature Pages Follow] 
  

 - 3 - 

 IN WITNESS WHEREOF, the parties hereto have executed this Omnibus Amendment effective as
of the day and year first above written. 
 COMPANY: 

 

			
	COMPLETE GENOMICS, INC.
		
	By:	 	          /s/ Clifford A. Reid            
		 	  Clifford A. Reid, President and
		 	  Chief Executive Officer
		
		 	Address for Notice:
		 	2071 Stierlin Court
		 	Mountain View, CA 94043

  

 SIGNATURE PAGE TO OMNIBUS AMENDMENT 

 STOCKHOLDERS: 

 

					
	 ESSEX WOODLANDS HEALTH VENTURES
FUND
 VIII, L.P.

		
	By:	 	 Essex Woodlands Health Ventures VIII,

L.P., its General Partner

			
		 	By:	 	Essex Woodlands Health Ventures
		 		 	VIII, LLC, its General Partner
			
		 	By:	 	     /s/ Jeff Himawan

		 	Name:	 	         Jeff Himawan

		 	Title: Manager
	
	 Address:
 Essex
Woodlands Health Ventures
 335 Bryant Street

Third Floor
 Palo Alto, CA
943010

	
	 ESSEX WOODLANDS HEALTH VENTURES
FUND
 VIII-A, L.P.

		
	By:	 	 Essex Woodlands Health Ventures VIII,

L.P., its General Partner

			
		 	By:	 	 Essex Woodlands Health Ventures

VIII, LLC, its General Partner

			
		 	By:	 	     /s/ Jeff Himawan

		 	Name:	 	         Jeff Himawan

		 	Title: Manager
	
	 Address:

Essex Woodlands Health Ventures
 335 Bryant
Street
 Third Floor
 Palo Alto, CA
943010

 SIGNATURE PAGE TO OMNIBUS AMENDMENT 

					
	 ESSEX WOODLANDS HEALTH VENTURES
FUND
 VIII-B, L.P.

		
	By:	 	Essex Woodlands Health Ventures VIII, L.P., its General Partner
			
		 	By:	 	Essex Woodlands Health Ventures
		 		 	VIII, LLC, its General Partner
			
		 	By:	 	     /s/ Jeff Himawan

		 	Name:	 	         Jeff Himawan

		 	Title: Manager
	
	 Address:
 Essex
Woodlands Health Ventures
 335 Bryant Street

Third Floor
 Palo Alto, CA
943010

  

 SIGNATURE PAGE TO OMNIBUS AMENDMENT 

 STOCKHOLDERS: 
  

  

			
	ORBIMED ASSOCIATES III, LP
		
	By:	 	     /s/ Carl Gordon

		 	       Carl L. Gordon, Ph.D., CFA

      General Partner

	
	 Address:
 OrbiMed
Advisors, LLC
 767 Third Avenue

Thirtieth Floor
 New York, NY
10017

	
	CADUCEUS PRIVATE INVESTMENTS III, LP
		
	By:	 	     /s/ Carl Gordon

		 	       Carl L. Gordon, Ph.D., CFA

      General Partner

	
	 Address:
 OrbiMed
Advisors, LLC
 767 Third Avenue

Thirtieth Floor
 New York, NY
10017

  

 SIGNATURE PAGE TO OMNIBUS AMENDMENT 

 STOCKHOLDERS: 
  

  

			
	HIGHLAND CRUSADER OFFSHORE PARTNERS, L.P.
	By: Highland Crusader Fund GP, L.P.
	Its: General Partner
	By: Highland Crusader GP, LLC.
	By: Highland Capital Management, L.P.
	Its: Sole Member
	By: Strand Advisors, Inc.
	Its: General Partner
	
	
                /s/ Jason
Post

	Name:	 	Jason Post
	Title:	 	Operations Director

  

			
	 HIGHLAND CREDIT OPPORTUNITIES

CDO L.P.

	By: Highland Credit Opportunities CDO GP, L.P.
	Its: General Partner
	By: Highland Credit Opportunities CDO GP, LLC
	Its: General Partner
	By: Highland Capital Management, L.P.
	Its: Sole Member
	By: Strand Advisors, Inc.
	Its: General Partner
	
	
                /s/ Jason
Post

	Name:	 	Jason Post
	Title:	 	Operations Director

  

 SIGNATURE PAGE TO OMNIBUS AMENDMENT 

 STOCKHOLDERS: 
  

  

			
	OVP VENTURE PARTNERS VI, L.P.
	By:	 	OVMC VI, LLC, as General Partner
		
	By:	 	                 /s/
Chad Waite

		 	Managing Member or Attorney In Fact
	
	 Address:
 OVP
Venture Partners
 1010 Market Street

Kirkland, WA 98033

	
	OVP VI ENTREPRENEURS FUND, L.P.
	By:	 	OVMC VI, LLC, as General Partner
		
	By:	 	                 /s/
Chad Waite

		 	Managing Member or Attorney In Fact
	
	 Address:
 OVP
Venture Partners
 1010 Market Street

Kirkland, WA 98033

  

 SIGNATURE PAGE TO OMNIBUS AMENDMENT 

 STOCKHOLDERS: 
  

  

			
	ENTERPRISE PARTNERS V, LP
	By:	 	Enterprise Management Partners V, LLC
		 	as General Partner
	
	         /s/ Andrew E. Senyei

	By:	 	Andrew E. Senyei
		 	Managing Director
	
	 Address:
 2223
Avenida de la Playa
 Suite 300
 La
Jolla CA 92037

	
	ENTERPRISE PARTNERS VI, LP
	By:	 	Enterprise Management Partners VI, LLC as
		 	General Partner
	
	         /s/ Andrew E. Senyei

	By:	 	Andrew E. Senyei
		 	Managing Director
	
	 Address:
 2223
Avenida de la Playa
 Suite 300
 La
Jolla CA 92037

  

 SIGNATURE PAGE TO OMNIBUS AMENDMENT 

 STOCKHOLDERS: 
  

  

			
	PROSPECT VENTURE PARTNERS III, L.P.
		
	By:	 	Prospect Management Co. III, L.L.C.
	Its:	 	General Partner
	
	             /s/ Alex
Barkas

	By:	 	
	Title:	 	Managing Director
	
	 Address:
 Prospect
Venture Partners
 435 Tasso Street

Suite 200
 Palo Alto, CA
94301

  

 SIGNATURE PAGE TO OMNIBUS AMENDMENT 

 STOCKHOLDERS: 
  

  

			
	THE MENDELSON FAMILY TRUST
	
	         /s/ Alan C. Mendelson

	By:	 	Alan Mendelson
	Title:	 	Trustee
	
	 Address:
 76 De
Bell Drive
 Atherton, CA 94027

	
	VP COMPANY INVESTMENTS 2008, LLC
	
	         /s/ Alan C. Mendelson

	By:	 	Alan Mendelson
	Title:	 	Trustee
	
	 Address:
 c/o
Latham & Watkins LLP
 555 West Fifth Street

Suite 800
 Los Angeles, CA
90013-1021

  

 SIGNATURE PAGE TO OMNIBUS AMENDMENT 

 STOCKHOLDERS: 
  

  

			
	AQUILO PARTNERS, L.P.
	
	         /s/ James F. Zanze

	By: James F. Zanze
	Title: Managing Director
	
	 Address:
 One
Maritime Plaza
 Suite 1570
 San
Francisco, CA 94111

  

 SIGNATURE PAGE TO OMNIBUS AMENDMENT 

 SIGNIFICANT COMMON STOCK HOLDERS: 

 

	
	THE CURSON FAMILY LIVING TRUST DATED JULY 30,
2001
	
	 /s/ Robert John Curson

	Robert John Curson, Trustee
	 Address:
 135 Ponderosa Drive

 Santa Cruz, CA 95060

	
	DRMANAC FAMILY TRUST DATED JUNE 21, 2000
	
	 /s/ Radoje Drmanac

	Radoje Drmanac, Trustee
	 Address:
 27635 Red Rock Road

 Los Altos Hills, CA 94022

	
	 CLIFFORD A. REID LIVING TRUST, DATED

 SEPTEMBER 3, 1997

	
	 /s/ Clifford A. Reid

	Clifford A. Reid, Trustee
	 Address:
 151 Blackburn Terrace

 Pacifica, CA 94044

  

 SIGNATURE PAGE TO OMNIBUS AMENDMENT 

 EXHIBIT A 

Investors 
  

			
	Investor	  	 Number of

Shares *

	 Essex Woodlands Health Ventures Fund VIII, L.P.
	  	1,798,115
	 Essex Woodlands Health Ventures Fund VIII –A, L.P.
	  	129,644
	 Essex Woodlands Health Ventures Fund VIII-B, L.P.
	  	56,367
	 Orbimed Associates III
	  	18,718
	 Caduceus Private Investments III
	  	1,965,408
	 Highland Crusader Offshore Partners, L.P.
	  	1,249,214
	 Highland Credit Opportunities CDO, L.P.
	  	362,122
	 Genentech, Inc.
	  	85,888
	 OVP Venture Partners VI, L.P.
	  	1,793,502
	 OVP VI Entrepreneurs Fund L.P.
	  	27,725
	 Enterprise Partners VI, LP
	  	1,490,106
	 Enterprise Partners V, LP
	  	331,133
	 VP Company Investments 2004, LLC
	  	5,323
	 VP Company Investments 2008, LLC
	  	5,521
	 The Mendelson Family Trust
	  	10,844
	 Prospect Venture Partners III, L.P.
	  	1,730,366
	 Gold Hill Venture Lending 03, LP
	  	32,729
	 Aquilo Partners, L.P.
	  	11,986

 * For the avoidance of
confusion, it is noted that the numbers above include certain shares and/or warrants that are not taken into account in the calculations of “Co-Sale Pro Rata Portion” and “ROFR Pro Rata Portion” under this Agreement.

  

 1 

 EXHIBIT B 

Significant Common Holders 
  

			
	 Significant Common Holders
	  	Number of Shares
		
	 Clifford A. Reid Living Trust, Dated September 3, 1997
	  	33,333
	 Drmanac Family Trust Dated June 21, 2000
	  	33,333
	 The Curson Family Living Trust Dated July 30, 2001
	  	11,666

  

 2 

 OMNIBUS AMENDMENT 

This Omnibus Amendment, dated as of February 16, 2010 (this “Omnibus Amendment”), amends (i) that
certain Series D Preferred Stock Purchase Agreement dated as of August 12, 2009 (the “Purchase Agreement”), among Complete Genomics, Inc., a Delaware corporation (the “Company”), and the entities
and individuals listed on Exhibit A thereto (each an “Investor” and together the “Investors”), (ii) that certain Third Amended and Restated Investor Rights Agreement, dated as of
August 12, 2009, as amended on November 6, 2009, among the Company, the Investors (as defined therein) and the Founders (as defined therein) (“the “IRA”), (iii) that certain Third Amended and Restated
Right of First Refusal and Co-Sale Agreement, dated as of August 12, 2009, as amended on November 6, 2009, among the Investors (as defined therein), the Founders (as defined therein) and the Company (the “ROFR
Agreement”) and (iii) that certain Third Amended and Restated Voting Agreement, dated as of August 12, 2009, as amended on November 6, 2009, among the Company and the Stockholders (as defined therein) (the
“Voting Agreement” together with the Purchase Agreement, the IRA and the ROFR Agreement, the “Agreements”). 

RECITALS 

WHEREAS, the Company and the undersigned Investors desire to amend the Purchase Agreement to add an additional closing to the
Purchase Agreement to (i) provide for the issuance of an additional 1,346,762 shares of Series D Preferred Stock of the Company (the “Series D Extension Financing”), (ii) add C. Thomas Caskey to the Agreement as an
Investor and (iii) to effect certain other related changes. 
 WHEREAS, in connection with the Series D Extension
Financing, the Company and the undersigned Investors desire to make certain conforming amendments to the IRA, the ROFR Agreement and the Voting Agreement. 

WHEREAS, Section 6.10 of the Purchase Agreement provides that the Purchase Agreement may be amended or waived only with the
written consent of the Company and the holders of a majority of the Common Stock issuable or issued upon conversion of the Shares (as defined therein) (the “Purchase Agreement Threshold”). 

WHEREAS, Section 5.10 of the IRA provides that the IRA may be amended with the written consent of the Company and Holders (as
defined therein) of more than sixty percent (60%) of the outstanding shares of Common Stock issued or issuable pursuant to conversion of the Shares (as defined therein) (the “IRA Amendment Threshold”). 

WHEREAS, Section 10.10 of the ROFR Agreement provides that the ROFR Agreement may be amended with the written consent of the
Company, the Significant Common Stock Holders (as defined therein) holding, in the aggregate, a majority of the outstanding shares held by all Significant Common Stock Holders and any individual Investor (as defined therein) or group of Investors
holding, in the aggregate, more than sixty percent (60%) of the common stock issued or issuable upon conversion of the Preferred Stock held by all Investors (the “ROFR Agreement Amendment Threshold”). 

 

 1 

 WHEREAS, Section 10.9 of the Voting Agreement provides that the Voting Agreement
may be amended with the written consent of the Company, the holders of at least a majority of the outstanding Common Stock of the Company and the holders of at least sixty percent (60%) of the outstanding Preferred Stock of the Company (the
“Voting Agreement Amendment Threshold”). 
 WHEREAS, The undersigned
constitute each of the Purchase Agreement Threshold, the IRA Amendment Threshold, the ROFR Agreement Amendment Threshold and the Voting Agreement Amendment Threshold. 

NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, agree as follows: 

1. Amendments. 

(A) Section 1.1 of the Purchase Agreement is hereby amended and restated to read in its entirety as follows: 

“1.1 Sale and Issuance of Series D Preferred Stock. 

(a) The Company shall adopt and file with the Secretary of State of the State of Delaware on or before the Initial Closing (as defined
below in Section 1.3(a)) the Fourth Restated Certificate of Incorporation in the form attached hereto as Exhibit B (the “Fourth Restated Certificate”). The Company shall adopt and file with the Secretary of
State of the State of Delaware on or before the 2010 Initial Closing (as defined below in Section 1.3(c)) the Sixth Restated Certificate of Incorporation in the form attached hereto as Exhibit B-1 (the “Sixth Restated
Certificate”). The term “Restated Certificate” as used herein shall, prior to the 2010 Initial Closing, refer to the Fourth Restated Certificate and from and after the 2010 Initial Closing shall refer to the
Sixth Restated Certificate. 
 (b) Subject to the terms and conditions of this Agreement, each Investor agrees, severally and
not jointly, to purchase at the applicable Closing, and the Company agrees, severally and not jointly, to sell and issue to each Investor at the applicable Closing, that number of shares of the Company’s Series D Preferred Stock (the
“Series D Preferred”) set forth opposite each Investor’s name on Exhibit A hereto at a purchase price of $0.252 per share (if such Shares are purchased at the Initial Closing) or $7.56 per share (if such
Shares are purchased at the 2010 Initial Closing). The shares of Series D Preferred to be sold pursuant to this Agreement are collectively referred to herein as the “Shares.” The Shares will have the rights, preferences,
privileges and restrictions set forth in the Restated Certificate or the Sixth Restated Certificate, as applicable.” 
 (B)
Exhibit A of the Purchase Agreement is hereby amended to read in its entirety as set forth on Exhibit A hereto. 

(C) Exhibit B-1 is hereby added to the Purchase Agreement to read in its entirety as set forth on Exhibit B-1 hereto.

  

 2 

 (D) Section 1.3(c) of the Purchase Agreement is hereby amended and restated to read in
its entirety as follows and Sections 1.3(d), (e) and (f) of the Agreement are hereby added to read in their entirety as follows: 

“(c) The purchase and sale of Shares listed on Exhibit A hereto under the heading “2010 Initial Closing” shall
take place at the offices of Latham & Watkins LLP at 12:00 p.m. on February 16, 2010, or at such other time and place as the Company and Investors acquiring in the aggregate more than half of the Shares at such Closing shall mutually
agree (which time and place are designated as the “2010 Initial Closing”). 
 (d)
At any time on or before the fifteenth (15th) day
following the 2010 Initial Closing or at such later time as the Company and the Majority Holders shall mutually agree upon, the Company may sell to persons or entities (and their affiliates) listed on Exhibit A-1 hereto under the heading
“2010 Additional Closing” the number of shares of Series D Preferred set forth next to such person’s or entity’s name (the “2010 Additional Closing”). All such sales made at the 2010 Additional Closing
shall be made on the terms and conditions set forth in this Agreement. The representations and warranties of the Company set forth in Section 2 hereof (and the Schedule of Exceptions) shall speak as of the 2010 Initial Closing and the Company
shall have no obligation to update any such disclosure. The representations and warranties of investor(s) participating in the 2010 Additional Closing (each, an “2010 Additional Closing Investor”) shall speak as of such 2010
Additional Closing. The Schedule of Investors may be amended by the Company without the consent of the Investors to reflect the date of the 2010 Additional Closing and the number of Shares purchased by any 2010 Additional Closing Investor in
accordance with this Section 1.3(d) upon the execution by such Additional Closing Investor of a counterpart signature page to this Amendment (and, if the 2010 Additional Closing Investor was not an Additional Closing Investor, the Ancillary
Agreements), making such purchaser a party to and bound by the terms and conditions of this Agreement, as amended, and the Ancillary Agreements. Any shares of Series D Preferred sold pursuant to this Section 1.3(d) shall be deemed to be
“Shares” for all purposes under this Agreement and each 2010 Additional Closing Investor shall be deemed to be an “Investor” for all purposes under this Agreement. For the avoidance of doubt, without the prior written consent of
the Majority Holders the Company may not sell any additional Shares at the 2010 Additional Closing except in the amounts, and to the 2010 Additional Closing Investors, in each case that are listed on Exhibit A-1 as of the date of the 2010
Initial Closing. 
  

 3 

 (e) If any of Essex Woodlands Health Ventures Fund VIII, L.P., Essex Woodlands Health
Ventures Fund VIII-A, L.P. and Essex Woodlands Health Ventures Fund VIII-B, L.P. (collectively, “Essex”), OrbiMed Associates III, LP and Caduceus Private Investments III, LP (collectively, “OrbiMed”),
Highland Capital Management, L.P. (“Highland”), Prospect Venture Partners III, L.P. (“Prospect”), OVP Venture Partners VI, L.P. and OVP VI Entrepreneurs Fund, L.P. (collectively,
“OVP”) and Enterprise Partners VI, LP and Enterprise Partners V, LP (collectively, “Enterprise”), together with their respective affiliates (the “Major Investors”), do not
purchase their pro rata portion (calculated by comparing the ratio of the number of shares of Preferred Stock held by such Major Investor to the number of shares of Preferred Stock held by all Major Investors, each on an as-converted to Common Stock
basis, the “Pro Rata Portion”) of Ten Million dollars ($10,000,000) (the “Extension Amount”) at either the 2010 Initial Closing or the 2010 Additional Closing, each Major Investors who purchases its
Pro Rata Portion of the Extension Amount (the “Participating Major Investors”) shall have the right, but not the obligation, to purchase up to the remaining portion that the Major Investors failed to exercise (the
“Over-Allotment Shares”); provided, that if the Major Investors with such over-allotment right exercise such right for an aggregate number in excess of such Over-Allotment Shares, the Over-Allotment Shares shall be allocated
among them in accordance with their respective Pro Rata Portions (or in such other manner as such Participating Major Investors agree). The sale of the Over-Allotment Shares shall take place within fifteen (15) days after the 2010 Additional
Closing (the “Over-Allotment Closing”) and such sale shall be made on the terms and conditions set forth in this Agreement. The representations and warranties of the Company set forth in Section 2 hereof (and the
Schedule of Exceptions) shall speak as of the 2010 Initial Closing and the Company shall have no obligation to update any such disclosure. The representations and warranties of investor(s) participating in the Over-Allotment Closing (each, an
“Over-Allotment Investor”) shall speak as of the Over-Allotment Closing. The Schedule of Investors may be amended by the Company without the consent of the Investors to reflect the date of the Over-Allotment Closing and the
number of Shares purchased by any Over-Allotment Investor in accordance with this Section 1.3(e). Any shares of Series D Preferred sold pursuant to this Section 1.3(e) shall be deemed to be “Shares” for all purposes under this
Agreement. 
 (f) As soon as practicable after each Closing, the Company shall deliver to each Investor a certificate or
certificates representing that number of Shares set forth opposite such Investor’s name on Exhibit A hereto and, if applicable, the Warrants, against payment of the purchase price therefor by check, wire transfer, cancellation of
indebtedness, any combination of the foregoing, or such other forms of payment as may be approved by the Company’s Board of Directors (the “Board”).” 

(E) Exhibit A-1 of the Purchase Agreement is hereby amended to read in its entirety as set forth on Exhibit A-1 hereto.

 (F) The introductory clause of Section 2 of the Purchase Agreement is hereby amended to read in its entirety as follows:

 “2 Representations and Warranties of the Company. The Company hereby represents and warrants to each Investor as
of the Initial Closing or the 2010 Initial Closing, as applicable, except where another date is specified in such representation or warranty and except 

 

 4 

 
as set forth in the Schedule of Exceptions attached hereto as Exhibit F, which Schedule of Exceptions shall be updated as of the 2010 Initial Closing and attached hereto as Exhibit
F-1 (each, the “Schedule of Exceptions”), specifically identifying the relevant subparagraph(s) hereof, which exceptions shall be deemed to be representations and warranties hereunder:” 

(G) The last sentence of Section 2 of the Purchase Agreement is hereby amended to read in its entirety as follows: 

“True and accurate copies of the Company’s Certificate of Incorporation and Bylaws, each as amended and in effect at the
Initial Closing and the 2010 Initial Closing, have been made available to the Investors.” 
 (H) Clause (i) of
Section 2.4 of the Purchase Agreement is hereby amended and restated in its entirety as follows: 
 “(i) the filing of
the Fourth Restated Certificate in the office of the Secretary of State of the State of Delaware, which has been filed by the Company prior to the Initial Closing or, with respect to the 2010 Initial Closing or the 2010 Additional Closing, the
filing of the Sixth Restated Certificate in the office of the Secretary of State of the State of Delaware, which has been filed by the Company prior to the 2010 Initial Closing.” 

(I) The first sentence of Section 2.8 of the Purchase Agreement is hereby amended and restated in its entirety as follows:

 “The Company is not in violation or default of any provision of its Certificate of Incorporation or Bylaws, each as
amended and in effect as of the Initial Closing or the 2010 Initial Closing, as applicable.” 
 (J) The first sentence of
Section 2.24 of the Purchase Agreement is hereby amended and restated in its entirety as follows: 
 “The Company has
made available to each Investor the audited balance sheet, income statement and statement of cash flows of the Company as of and for the period ended December 31, 2008 and the unaudited balance sheet, income statement and statements of cash
flows of the Company as, of and for the nine (9) month period ended September 30, 2009, with respect to the 2010 Initial Closing) (collectively, the “Financial Statements”).” 

(K) The fourth sentence of Section 2.24 of the Purchase Agreement is hereby amended and restated in its entirety as follows:

 “Except as set forth in the Financial Statements, the Company has no material liabilities or obligations, contingent or
otherwise, other than (i) liabilities incurred in the ordinary course of business subsequent to September 30, 2009 and (ii) obligations under contracts and commitments incurred in the ordinary course of business and not required under
generally accepted accounting principles to be reflected in the Financial Statements, which, in both cases, individually or in the aggregate are not material to the financial condition or operating results of the Company.” 

 

 5 

 (L) The introductory clause of Section 2.25 of the Purchase Agreement is hereby amended
and restated in its entirety as follows: 
 “2.25 Changes. Since September 30, 2009, there has not been:”

 (M) The introductory clause of Section 3 of the Purchase Agreement is hereby amended and restated in its entirety as
follows: 
 “3 Representations and Warranties of the Investors. Each Investor hereby severally represents and
warrants as of each Closing at which such Investor purchases Shares as follows:” 
 (N) Section 4.1 of the Purchase
Agreement is hereby amended and restated in its entirety as follows: 
 “4.1 Representations and Warranties. The
representations and warranties of the Company contained in Section 2 shall be true on and as of the Initial Closing and the 2010 Initial Closing with the same effect as though such representations and warranties had been made on and as of the
date of the Initial Closing or the 2010 Initial Closing, as applicable.” 
 (O) Section 4.4 of the Purchase Agreement
is hereby amended and restated in its entirety as follows: 
 “4.4 Restated Certificate. The Fourth Restated
Certificate shall have been filed with the Secretary of State of Delaware prior to the Initial Closing and the Sixth Restated Certificate shall have been filed with the State of Delaware prior to the 2010 Initial Closing.” 

(P) Section 4.8 of the Purchase Agreement is hereby amended and restated in its entirety as follows: 

“4.8 Opinion of Company Counsel. The Investors shall have received from Latham & Watkins LLP, counsel for the
Company, an opinion, dated as of the Initial Closing or the 2010 Initial Closing, as applicable, in the form attached hereto as Exhibit G.” 

(Q) Section 6.8 of the Purchase Agreement is hereby amended and restated in its entirety as follows: 

“6.8 Expenses. The Company and each Investor shall bear their own expenses and legal fees incurred on their behalf with
respect to this Agreement and the transactions contemplated hereby; provided, however, that promptly after the Initial Closing, the Company shall pay reasonable out of pocket legal fees and expenses incurred in connection with the
transactions contemplated by this Agreement, including review of intellectual property, of Essex and OrbiMed (the “New Investors”) in an amount not to exceed $175,000 in the aggregate, and the reasonable out of pocket legal
fees and expenses incurred in connection with the transactions contemplated by this Agreement of one counsel to certain of the Investors (other than the New Investors) in an amount not to exceed $30,000 in the aggregate. The Company shall also
reimburse Essex, or pay at the discretion of Essex, the reasonable legal fees and expenses of Essex incurred in connection with any waiver, amendment or modification of this Agreement or 

 

 6 

 
the Ancillary Agreements that is requested by the Company. Promptly after the 2010 Initial Closing, the Company shall pay the reasonable out of pocket legal fees and expenses incurred by one
counsel to the New Investors in connection with the Series D Extension Financing, as supported by a detailed invoice in an amount not to exceed $10,000 in the aggregate.” 

(R) Any reference to the Company’s Fifth Restated Certificate of Incorporation in the IRA, the ROFR Agreement or the Voting
Agreement shall hereafter be deemed to be a reference to the Company’s Sixth Restated Certificate of Incorporation, as may be amended from time to time. 

2. Reference to and Effect on the Agreements. On or after the date hereof, each reference in the Agreements to “this
Agreement,” “hereunder,” “herein” or words of like import shall mean and be a reference to the Agreements as amended hereby. No reference to this Amendment need be made in any instrument or document at any time referring to
the Agreements, a reference to the Agreements in any of such to be deemed a reference to the Agreements as amended hereby. 
 3.
No Other Amendments. Except as set forth herein, the Agreements shall remain in full force and effect in accordance with their terms. 

4. Counterparts. This Amendment may be executed in any number of counterparts, each of which may be executed by less than all of
the parties, each of which shall be enforceable against the parties actually executing such counterparts, and all of which together shall constitute one instrument. 

5. Definitions. Capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the Purchase
Agreement. 
 6. Headings. All section headings herein are inserted for convenience only and shall not modify or affect
the construction or interpretation of any provisions of this Amendment or the Agreements. 
 7. Governing Law. This
Amendment and all acts and transactions pursuant hereto and the rights and obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the State of California, without giving effect to principles of
conflicts of law. 
 (Signature pages follow) 

 

 7 

 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first
above written. 
  

	
	Complete Genomics, Inc.
	
	     /s/ Clifford A. Reid

	Clifford A. Reid, President and
	Chief Executive Officer
	
	Address for Notice:
	 2071 Stierlin Court
 Mountain
View, CA 94043

 SIGNATURE PAGE TO COMPLETE GENOMICS, INC. OMNIBUS AMENDMENT 

IN CONNECTION WITH SERIES D EXTENSION FINANCING 

 Investors: 

 

							
	 ESSEX WOODLANDS HEALTH VENTURES FUND VIII, L.P.

		
	 By:
	 	 ESSEX WOODLANDS HEALTH VENTURES VIII, L.P.

Its General Partner

			
		 	 By:
	 	 ESSEX WOODLANDS HEALTH VENTURES VIII, LLC

Its General Partner

				
		 		 	By:	 	     /s/ Jeff Himawan

		 		 	Name:	 	     Jeff Himawan

		 		 	Title:	 	    Manager
		
	Address:	 	 335 Bryant Street

			
		 		 	 Palo Alto, CA 94301

		 		 	 Attn: Jeff Himawan

		
	Fax No:	 	 (650) 327-9755

	
	 ESSEX WOODLANDS HEALTH VENTURES FUND VIII-A, L.P.

		
	 By:
	 	 ESSEX WOODLANDS HEALTH VENTURES VIII, L.P.

Its General Partner

			
		 	 By:
	 	 ESSEX WOODLANDS HEALTH VENTURES VIII, LLC

Its General Partner

				
		 		 	By:	 	     /s/ Jeff Himawan

		 		 	 Name:
 Title:
	 	     Jeff Himawan

    Manager

		
	Address:	 	 335 Bryant Street

		 		 	 Palo Alto, CA 94301

		 		 	 Attn: Jeff Himawan

	Fax No:	 	 (650) 327-9755

  

 SIGNATURE PAGE TO COMPLETE GENOMICS, INC. OMNIBUS AMENDMENT 

IN CONNECTION WITH SERIES D EXTENSION FINANCING 

 Investors: 

 

  

							
	 ESSEX WOODLANDS HEALTH VENTURES FUND VIII-B, L.P.

		
	 By:
	 	 ESSEX WOODLANDS HEALTH VENTURES VIII, L.P.

Its General Partner

			
		 	 By:
	 	 ESSEX WOODLANDS HEALTH VENTURES VIII, LLC

Its General Partner

				
		 		 	By:	 	     /s/ Jeff Himawan

		 		 	 Name:
	 	     Jeff Himawan

		 		 	 Title:
	 	     Manager 

		
	Address:	 	 335 Bryant Street

		 		 	 Palo Alto, CA 94301

		 		 	 Attn: Jeff Himawan

	Fax No:	 	 (650) 327-9755

  

 SIGNATURE PAGE TO COMPLETE GENOMICS, INC. OMNIBUS AMENDMENT 

IN CONNECTION WITH SERIES D EXTENSION FINANCING 

 Investors: 

 

  

			
	ORBIMED ASSOCIATES III, LP
		
	By:	 	     /s/ Carl Gordon

		 	Carl Gordon
		 	General Partner
	
	 Address: 767 Third Avenue,
30th Floor

New York, NY 10017

	
	 CADUCEUS PRIVATE INVESTMENTS III, LP

		
	By:	 	     /s/ Carl Gordon

		 	Carl Gordon
		 	General Partner
	
	 Address: 767 Third Avenue,
30th Floor

New York, NY 10017

  

 SIGNATURE PAGE TO COMPLETE GENOMICS, INC. OMNIBUS AMENDMENT 

IN CONNECTION WITH SERIES D EXTENSION FINANCING 

 Investors: 

 

  

			
	OVP Venture Partners VI, L.P.
	By:	 	OVMC VI, LLC, as General Partner

			
		
	By:	 	             /s/ Chad
Waite

		 	Managing Member or Attorney In Fact
	
	 Address:

	
	OVP VI Entrepreneurs Fund, L.P.
	By:	 	OVMC VI, LLC, as General Partner

			
		
	By:	 	             /s/ Chad
Waite

		 	Managing Member or Attorney In Fact
	
	 Address:

  

 SIGNATURE PAGE TO COMPLETE GENOMICS, INC. OMNIBUS AMENDMENT 

IN CONNECTION WITH SERIES D EXTENSION FINANCING 

 Investors: 

 

  

			
	Enterprise Partners VI, LP
	By:	 	 Enterprise Management Partners VI,

LLC as General Partner

	
	 /s/ Andrew E. Senyei

	By:	 	Andrew E. Senyei
		 	Managing Director

 

			
	Address:	 	2223 Avenida de la Playa
		 	La Jolla CA 92037

 

			
	 Enterprise Partners V, LP

	By:	 	 Enterprise Management Partners V,

LLC as General Partner

	
	 /s/ Andrew E. Senyei

	By:	 	Andrew E. Senyei
		 	Managing Director

 

			
	Address:	 	2223 Avenida de la Playa
		 	La Jolla CA 92037
	
	 Enterprise Partners Management, LLC

	
	 /s/ Andrew E. Senyei

	 Andrew E. Senyei

	 As sole Director of Andrew E. Senyei, Inc.

	 Manager of Enterprise Partners

Management, LLC

		
	Address:	 	2223 Avenida de la Playa
		 	La Jolla CA 92037

  

 SIGNATURE PAGE TO COMPLETE GENOMICS, INC. OMNIBUS AMENDMENT 

IN CONNECTION WITH SERIES D EXTENSION FINANCING 

 Investors: 

 

  

			
	Prospect Venture Partners III, L.P.
		
	By:	 	Prospect Management Co. III, L.L.C.
	Its:	 	General Partner
	
	 /s/ David Markland

	Name:	 	
	Title:	 	Managing Director or Attorney In Fact
	
	Address:

  

 SIGNATURE PAGE TO COMPLETE GENOMICS, INC. OMNIBUS AMENDMENT 

IN CONNECTION WITH SERIES D EXTENSION FINANCING 

 Investors: 

 

  

			
	HIGHLAND CRUSADER OFFSHORE PARTNERS, L.P.
	 By: Highland Crusader Fund GP, L.P., as General Partner

	By: Highland Crusader GP, LLC.
	 By: Highland Capital Management, L.P., as Sole Member

	By: Strand Advisors, Inc., as General Partner
		
	 By:
	 	         /s/ Mark Okada

	Name:	 	         Mark Okada

	Title: 	 	         Executive Vice President

	
	 HIGHLAND CREDIT OPPORTUNITIES CDO, L.P.

	 By: 
	 	Highland Crusader Fund GP, L.P., as General Partner
	By:	 	Highland Crusader GP, LLC.
	By: 	 	Highland Capital Management, L.P., as Sole Member
	By:	 	Strand Advisors, Inc., as General Partner
		
	By:	 	         /s/ Mark Okada

	Name:	 	         Mark Okada

	Title:	 	         Executive Vice
President

  

 SIGNATURE PAGE TO COMPLETE GENOMICS, INC. OMNIBUS AMENDMENT 

IN CONNECTION WITH SERIES D EXTENSION FINANCING 

 Investors: 

 

  

			
	Aquilo Partners, L.P.
		
	By:	 	
	Its:	 	
	
	 /s/ John Rumsey

	Name: John Rumsey
	Title: Managing Director
	
	Address:

  

 SIGNATURE PAGE TO COMPLETE GENOMICS, INC. OMNIBUS AMENDMENT 

IN CONNECTION WITH SERIES D EXTENSION FINANCING 

 Investors: 

 

  

			
	The Mendelson Family Trust
	
	     /s/ Alan C. Mendelson

	By:	 	Alan C. Mendelson
	Title:	 	Trustee
	
	 Address:
 76 De
Bell Drive
 Atherton, CA 94027

	
	 VP Company Investments 2008, LLC

	
	     /s/ Alan C. Mendelson

	By:	 	Alan C. Mendelson
	Title:	 	Managing Member
	
	Address: 555 West Fifth Street
	 Suite 800

	 Los Angeles, CA 90013

  

 SIGNATURE PAGE TO COMPLETE GENOMICS, INC. OMNIBUS AMENDMENT 

IN CONNECTION WITH SERIES D EXTENSION FINANCING 

 Investors: 

 

  

	
	C. Thomas Caskey
	
	         /s/ C. Thomas Caskey

	
	 Address:

	 Essex Woodlands Health Ventures

	 1825 Pressler Street

	 Suite 205

	 Houston, TX 77030

  

 SIGNATURE PAGE TO COMPLETE GENOMICS, INC. OMNIBUS AMENDMENT 

IN CONNECTION WITH SERIES D EXTENSION FINANCING 

 Investors: 

 

  

			
	Gold Hill Venture Lending 03 L.P.
	 By:
	 	 Gold Hill Venture Lending Partners

03, L.P., as General Partner 

	
	 /s/ Tim McDonough

	By:	 	 Tim McDonough 

	 Title:
	 	Principal, Gold Hill Capital
	
	 Address:

Gold Hill Capital
 One Almaden
Boulevard
 Suite 630
 San Jose, CA
95113

  

 SIGNATURE PAGE TO COMPLETE GENOMICS, INC. OMNIBUS AMENDMENT 

IN CONNECTION WITH SERIES D EXTENSION FINANCING 

 Investors: 

 

  

	
	Genentech, Inc.
	
	By:
	Its:
	
	         /s/ Robert Andreatta

	Name: Robert Andreatta
	Title: Vice President, Controller & Chief Accounting Officer
	
	Address:
	 1 DNA Way
 South San Francisco,
CA 94080

  

 SIGNATURE PAGE TO COMPLETE GENOMICS, INC. OMNIBUS AMENDMENT 

IN CONNECTION WITH SERIES D EXTENSION FINANCING 

 Significant Common Stockholders:* 

 

	
	THE CURSON FAMILY LIVING TRUST DATED JULY 30,
2001
	
	 /s/ Robert John Curson

	Robert John Curson, Trustee
	 Address:
 135 Ponderosa Drive

 Santa Cruz, CA 95060

	
	DRMANAC FAMILY TRUST DATED JUNE 21, 2000
	
	 /s/ Radoje Drmanac

	Radoje Drmanac, Trustee
	 Address:
 27635 Red Rock Road

 Los Altos Hills, CA 94022

	
	CLIFFORD A. REID LIVING TRUST, DATED SEPTEMBER 3, 1997
	
	 /s/ Clifford A. Reid

	Clifford A. Reid, Trustee
	 Address:
 151 Blackburn Terrace

 Pacifica, CA 94044

 
 * Signing for purposes of amendment of
Right of First Refusal and Co-Sale Agreement and Voting Agreement only. 
 SIGNATURE PAGE TO COMPLETE GENOMICS, INC. OMNIBUS
AMENDMENT 
 IN CONNECTION WITH SERIES D EXTENSION FINANCING 

 

 Founders:* 

 

	
	ROBERT JOHN CURSON
	
	 /s/ Robert John Curson

	
	 Address:
 135 Ponderosa Drive

 Santa Cruz, CA 95060

	
	RADOJE DRMANAC
	
	 /s/ Radoje Drmanac

	
	 Address:
 27635 Red Rock Road

 Los Altos Hills, CA 94022

	
	CLIFFORD A. REID
	
	 /s/ Clifford A. Reid

	
	 Address:
 151 Blackburn Terrace

 Pacifica, CA 94044

 
 * Signing for purposes of amendment of
Right of First Refusal and Co-Sale Agreement and Voting Agreement only. 
 SIGNATURE PAGE TO COMPLETE GENOMICS, INC. OMNIBUS
AMENDMENT 
 IN CONNECTION WITH SERIES D EXTENSION FINANCING 

 

 EXHIBIT A 

SCHEDULE OF INVESTORS 

Initial Closing – August 12, 2009 
  

							
	Investor	  	Number of
Shares 	  	Aggregate Purchase
Price	 	Common Stock
Warrants
				
	 Essex Woodlands Health Ventures Fund VIII
	  	53,943,453	  	$13,593,750.16	 	0
	 Essex Woodlands Health Ventures Fund VIII -A
	  	3,889,340	  	$980,113.68	 	0
	 Essex Woodlands Health Ventures Fund VIII-B
	  	1,691,017	  	$426,136.29	 	0
	 Orbimed Associates III
	  	561,548	  	$141,510.10	 	0
	 Caduceus Private Investments III
	  	58,962,262	  	$14,858,490.03	 	0
	 Highland Crusader Offshore Partners, L.P.
	  	12,237,678	  	$3,083,894.86(1)
	 	9,889,156
	 OVP Venture Partners VI, L.P.
	  	16,031,186	  	$4,039,858.88(2)
	 	13,337,730
	 OVP VI Entrepreneurs Fund, L.P.
	  	244,608	  	$61,641.22(3)
	 	94,022
	 Enterprise Partners VI, LP
	  	11,274,790	  	$2,841,247.08(4)
	 	9,267,909
	 Enterprise Partners V, L.P.
	  	5,001,004	  	$1,260,253.01(5)
	 	4,163,843
	 Prospect Venture Partners III, L.P.
	  	14,734,541	  	$3,713,104.34(6)
	 	12,166,279
	 The Mendelson Family Trust
	  	104,396	  	$26,307.80(7)
	 	0
	 VP Company Investments 2008, LLC
	  	104,396	  	$26,307.80(8)
	 	0
	 Aquilo Partners, L.P.
	  	96,253	  	$24,255.76(9)
	 	0

(1)
 $3,079,165.40 paid by conversion of Subordinated Convertible Promissory Notes dated February 13, 2009, April 6, 2009, June 12, 2009 and August 5, 2009.

(
2
) $4,033,857.77 paid by conversion of Subordinated
Convertible Promissory Notes dated February 13, 2009, April 6, 2009, June 12, 2009 and August 5, 2009. 

(3
) $61,549.54
 paid by conversion of Subordinated Convertible Promissory Notes dated February 13, 2009, April 6, 2009, June 12, 2009 and August 5, 2009. 

(4
) $2,835,154.23
 paid by conversion of Subordinated Convertible Promissory Notes dated February 13, 2009, April 6, 2009, June 12, 2009 and August 5, 2009. 

(5
) Paid
 by conversion of Subordinated Convertible Promissory Notes dated April 6, 2009 and June 12, 2009. 

(6
) $3,707,592.58
 paid by conversion of Subordinated Convertible Promissory Notes dated February 13, 2009, April 6, 2009, June 12, 2009 and August 5, 2009. 

(7
) Paid
 by conversion of Subordinated Convertible Promissory Notes dated March 4, 2009, April 6, 2009 and June 30, 2009. 

(8
) Paid
 by conversion of Subordinated Convertible Promissory Notes dated March 4, 2009, April 6, 2009 and June 30, 2009. 

(
9
) Paid by conversion of Subordinated Convertible
Promissory Notes dated March 4, 2009, April 6, 2009 and June 30, 2009. 
 2010 Initial Closing –
February 16, 2010 
  

					
	Investor	  	Number of
Shares	  	Aggregate Purchase
Price
			
	 Essex Woodlands Health Ventures Fund VIII
	  	263,019	  	$1,988,423.64
	 Essex Woodlands Health Ventures Fund VIII -A
	  	18,964	  	$143,367.84
	 Essex Woodlands Health Ventures Fund VIII-B
	  	8,245	  	$62,332.20
	 Orbimed Associates III
	  	2,738	  	$20,699.28
	 Caduceus Private Investments III
	  	287,490	  	$2,173,424.40
	 OVP Venture Partners VI, L.P.
	  	187,813	  	$1,419,866.28
	 OVP VI Entrepreneurs Fund, L.P.
	  	1,324	  	$10,009.44
	 Enterprise Partners Management, LLC
	  	66,138	  	$500,003.28
	 Enterprise Partners VI, LP
	  	112,963	  	$854,000.28
	 Enterprise Partners V, L.P.
	  	10,037	  	$75,879.72
	 Prospect Venture Partners III, L.P.
	  	183,275	  	$1,385,559.00
	Total	  	1,142,006	  	$8,633,565.36

 EXHIBIT A-1 

SCHEDULE OF INVESTORS/ADDITIONAL CLOSINGS 

Additional Closing – August 21, 2009 
  

					
	Investor	  	Number of
Shares	  	Aggregate Purchase
Price
			
	 The Mendelson Family Trust
	  	22,699	  	$5,720.15
	 VP Company Investments 2008, LLC
	  	22,699	  	$5,720.15
	 Aquilo Partners, L.P.
	  	20,928	  	$5,273.86

 2010 Additional Closing
– March 9, 2010 
  

							
	Investor	  	 Number

of
Shares
	  	 	  	 Aggregate

Purchase

Price

				
	 Highland Crusader Offshore Partners, L.P.
	  	127,774	  		  	$965,971.44
	 Highland Credit Opportunities CDO, L.P.
	  	52,969	  		  	$400,445.64
	 Genentech, Inc.
	  	12,366	  		  	$93,486.96
	 Aquilo Partners, L.P.
	  	1,653	  		  	$12,496.68
	 Gold Hill Venture Lending 03, LP
	  	3,723	  		  	$28,145.88
	 C. Thomas Caskey
	  	3,307	  		  	$25,000.92
	 The Mendelson Family Trust
	  	1,482	  		  	$11,203.92
	 VP Company Investments 2008, LLC
	  	1,482	  		  	$11,203.92
		  	204,756	  		  	$1,547,955.36

 EXHIBIT B-1 

SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00176-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00176-of-00352.parquet"}]]